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Abstract 
Mutations in the DMD gene result in Duchenne (DMD) and Becker (BMD) 
muscular dystrophies. The DMD gene encodes the protein, dystrophin that is 
predominantly expressed in skeletal muscle. Dystrophin is part of a larger protein 
complex known as the dystrophin-glycoprotein complex (DGC) and, as part of the DGC, 
provides a mechanical link between the sub-sarcolemmal cytoskeleton and the 
extracellular matrix. BMD is typically caused by mutations that maintain the reading 
frame and most often produce variable levels of internally truncated, partially functional 
dystrophin wheras DMD is most frequently characterized by a complete loss of 
dystrophin protein or disruption of key ligand binding domains. Utrophin has a highly 
similar overall structure to dystrophin and is part of the homologous utrophin-
glycoprotein complex (UGC) present during fetal development and is localized to 
neuromuscular and myotendinous junctions in adult muscle.  
Our lab has previously demonstrated that dystrophin protein in vitro thermal 
stability is sensitive to disease-causing missense mutations and internal deletions. In 
contrast, utrophin displays uniform stability upon internal deletion or terminal truncation. 
Several therapeutic strategies to treat DMD utilize internally deleted dystrophins, 
including the recently FDA approved exon-skipping drug, eteplirsen, as well as adeno-
associated virus (AAV) mediated delivery of therapeutic micro-dystrophins. Here, we 
characterized therapeutically relevant, internally truncated dystrophin constructs that 
have been proposed by leading scientists in the field. We show that, as a group, gene 
therapy micro-dystrophins are significantly less stable in vitro than full-length dystrophin 
whereas exon-skipped dystrophins have stability profiles congruent with full-length 
dystrophin.  
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To address the consequences of dystrophin instability in vivo, we generated two 
novel transgenic mouse models expressing missense mutant dystrophins reported in 
human DMD (L54R) and BMD (L172H) patients. The L54R and L172H missense 
mutants were previously evaluated in cultured myoblasts and shown to have missense-
mutant dystrophin levels that were inversely proportional to in vitro stability and disease 
severity of the corresponding patients. Analysis of the L54R and L172H mouse lines as 
well as a homozygous L172H mouse reveal that disease severity inversely correlates 
with expression levels of dystrophin protein. Based on the increase of mutant dystrophin 
upon proteasome inhibition in cultured myoblasts, our hypothesis is that missense 
dystrophin proteins are being targeted to the proteasome for degradation through the 
ubiquitin-proteasome pathway.  To determine the specific ligases involved in targeting 
missense dystrophins to the proteasome, we screened an siRNA library of over 500 
ubiquitin-conjugating enzymes in cultured myoblasts and identified five putative 
dystrophin-specific E3 ligases. Two of the identified ligases, Amn1 and FBXO33, were 
observed in our transgenic mouse lines, with Amn1 protein levels showing significant 
increases correlating with the amount of missense dystrophin present. Our future studies 
will continue to evaluate the impact of Amn1 and FBXO33 activity on dystrophin protein 
levels in order to identify potential therapeutic targets.  
In addition to the characterization of dystrophin and utrophin stability, we have 
begun to interrogate a long-hypothesized but understudied function of dystrophin and 
utrophin, namely, their roles as molecular springs to mechanically stabilize the muscle 
membrane during muscle contraction. Using atomic force microscopy (AFM), we show 
here the first mechanical characterization of utrophin and functionally relevant utrophin 
fragments. Our data reveal striking differences in the mechanical properties of N- and C-
terminal halves of utrophin despite having nearly identical thermal stabilities and high 
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structural homology. The high unfolding forces observed in utrophin and the evidence of 
stiffening spring behavior suggest that utrophin may be acting as a stiff elastic element in 
series with the giant muscle protein, titin, at the myotendinous junction. Future studies 
will include evaluation of myotendinous defects in utrophin-deficient mice as well as 
mechanical characterization of full-length dystrophin.  
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Chapter 1 
 
Introduction 
  2 
 
Duchenne Muscular Dystrophy and the DMD gene 
Disruptions in the structural components of the muscle fiber result in a wide 
variety of muscular dystrophies (Cohn and Campbell, 2000). One subtype, Duchenne 
muscular dystrophy (DMD), is an X-linked recessive disease and is the most prevalent of 
the muscular dystrophies affecting 1 in 4000 born males (Mendell et al., 2012). DMD, 
like many muscular dystrophies, is characterized by progressive muscle weakness and 
loss of motor function. The progression of DMD is typically high plasma levels of creatine 
kinase (CK) at birth (Zellweger and Antonik, 1975), muscle fiber hypertrophy during early 
childhood (Dennett et al., 1988), weakness of the proximal muscles (Gowers, 1886), loss 
of ambulation, and pulmonary and cardiac dysfunction towards the end of the second 
decade leading to death (Kohler et al., 2009). While there are some treatments to 
manage symptoms and improve quality of life, there is still no cure for DMD.  
 The gene mutated in DMD was identified in 1987 on the X chromosome and is 
the largest gene found in nature, spanning over 2.4 million base pairs (Koenig et al., 
1987). The DMD gene is transcribed into several different tissue specific transcripts from 
internal promoters and its full-length isoform contains 79 exons (Muntoni et al., 2003). 
The full length transcript encodes the protein dystrophin (discussed in greater detail 
below), which is predominantly expressed in skeletal muscle (Hoffman et al., 1987). 
One-third of DMD patients have de novo germline mutations with the remaining two 
thirds having heritable mutations passed down from asymptomatic or mildly affected 
female carriers (Flanigan, 2014).  
Mutations in the DMD gene can also lead to a milder form of the disease, Becker 
muscular dystrophy (BMD), which is typically caused by mutations that maintain the 
reading frame and most often produce variable levels of internally truncated, partially 
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functional dystrophin (Monaco et al., 1988; Koenig et al., 1989). In contrast, DMD is 
most frequently characterized by a complete loss of dystrophin protein or disruption of 
key ligand binding domains. Mutation types for DMD and BMD vary with 68.5% of 
patients harboring large deletions (>1 exon), 11% with duplications (>1 exon), 10% with 
non-sense mutations, 6% with smaller deletions or insertions (<1 exon), 3% with splice-
site mutations, and the remaining patients with rare mid-intronic or missense mutations 
(Figure 1.1, Bladen et al., 2015). Two mutational hot spots have been identified in exons 
2-20 and exons 45-55, with 80% of large deletions and 65% of duplications found in 
these regions (Oudet et al., 1992; Bladen et al., 2015). The genetic and phenotypic 
diversity found in DMD and BMD patients makes studying and treating the diseases very 
challenging but has also stimulated efforts to determine mechanisms of disease and to 
develop personalized therapies.  
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Dystrophin and Utrophin 
Dystrophin is a 427kDa rod-shaped protein comprised of an amino-terminal actin 
binding domain (ABD1), a central rod domain, a cysteine rich domain, and a carboxy-
terminal domain (Koenig et al., 1988). Due to its large size, a high-resolution structure of 
full-length dystrophin has not been determined, however, the crystal structures of 
individual domains have been solved.  The amino terminus contains a tandem calponin 
homology (CH) domain that binds actin filaments. The crystal structure revealed an α-
helical globular fold of the individual CH domains connected by an α-helix linker 
(Norwood et al., 2000). The carboxy terminus is composed of a cysteine rich (CR) region 
containing two EF-hand modules, a WW domain, and a ZZ domain, all of which are 
required for binding to the transmembrane protein β-dystroglycan. The central rod 
domain is the largest domain of dystrophin, containing 24 spectrin-type repeats. Spectrin 
repeats are independent motifs of left-handed, antiparallel, triple-helical coiled coils 
(Pascual et al., 1997). The dystrophin sequence was mapped using the spectrin repeat 
model that predicted similar triple-helical bundles but revealed unique, interspersed 
proline-rich regions within the dystrophin central rod domain (Koenig and Kunkel, 1990). 
These regions are designated as “hinges” and are thought to add flexibility to the rod-like 
structure or delineate three separate sub-domains (Legardinier et al., 2008). One 
proposed model for the structure of the central rod domain is that the spectrin-type 
repeat motifs are structurally “nested” within each other (Mirza et al., 2010). The crystal 
structure of dystrophin’s first repeat supports this model by revealing an extension of the 
structural domain at the C-terminus (Muthu et al., 2012).  
 Dystrophin is thought to function as a mechanical link between the cortical 
cytoskeleton and the extracellular matrix and has been shown to interact with a variety of 
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different proteins and lipids (Figure 1.2). At the N-terminus are binding domains for actin 
and keratin 19 (Way et al., 1992; Stone et al., 2005). Within the central rod is a second 
actin-binding domain (Rybakova et al., 1996) as well as domains for binding 
phospholipids, Par1b, neuronal nitric oxide synthase (nNOS), synemin, and microtubules 
(Legardinier et al., 2009b; Prins et al., 2009; Yamashita et al., 2010; Lai et al., 2013; 
Belanto et al., 2014). The cysteine-rich and C-terminal domains bind plectin, 
phospholipids, ankrin B/G, dystrobrevin, syntrophin, and β-dystroglycan (Suzuki et al., 
1992; Albrecht and Froehner, 2002; Hijikata et al., 2003; Ayalon et al., 2008; Legardinier 
et al., 2009b). Through these interactions, dystrophin is part of a larger, sub-
sarcolemmal protein assembly enriched at costameres, known as the dystrophin-
glycoprotein complex (DGC) (Figure 1.3, Ervasti and Campbell, 1991; Ervasti, 2007, 
2003). The core components of the DGC are dystrophin, α-dystrobrevin, and syntrophin, 
the sarcoglycans, sarcospan, β-dystroglycan, and α-dystroglycan. Mutations in many of 
the DGC proteins or proteins involved in their post-translational processing cause 
various forms of muscular dystrophy (reviewed in Rahimov and Kunkel 2013). Without 
the proper formation, localization, or function of the DGC, the sarcolemma becomes 
destabilized and more prone to contraction-induced damage with downstream effects of 
increased sarcolemmal permeability, cell death, and muscle degeneration. It is 
hypothesized that as a part of the DGC, dystrophin may potentially act as a molecular 
spring or “shock absorber” to mechanically stabilize the sarcolemma during muscle 
contraction (Ervasti, 2007). 
The protein utrophin was originally named dystrophin-related protein based on 
high sequence homology with dystrophin (Love et al., 1989). Due to its detection in 
tissues other than muscle and nerve (Khurana et al., 1990), it was later renamed 
utrophin, for ubiquitous dystrophin (Blake et al., 1992). The utrophin protein has a similar 
  6 
organizational structure to dystrophin with an N-terminal actin binding domain, a large 
central rod domain of spectrin-like repeats with interspersed “hinge” regions, and CR 
and C-terminal domains (Figure 1.2). Some properties in which utrophin differs from 
dystrophin include two fewer spectrin-like repeats, a contiguous actin binding domain 
from the N-terminus to repeat 10 (Rybakova et al., 2006), lack of microtubule binding 
(Belanto et al., 2014) and nNOS localization activities (Li et al., 2010). Like dystrophin, 
utrophin forms a homologous utrophin-glycoprotein complex (UGC), but is most 
abundantly expressed during fetal development and subsequently replaced by 
dystrophin at the sarcolemma after birth (Rigoletto et al., 1995). In adult skeletal muscle, 
utrophin localizes to the neuromuscular and myotendinous junctions (Ohlendieck et al., 
1991).  
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Therapeutic Strategies to Treat DMD  
 Genetic approaches to treat DMD have shown tremendous promise in pre-
clinical studies and many have been fast-tracked to clinical trials where there has been 
variable success. Traditional gene therapy approaches of replacing the mutated DMD 
gene have focused on the use of an adeno-associated viruses (AAV). The limited 
capacity of AAV vectors requires the use of miniaturized dystrophins (or “micro-
dystrophins”) with large internal deletions in the central rod domain, of which there have 
been several proposed constructs showing efficacy in dystrophin-deficient animal 
models (Wang et al., 2000, 2007; Lai et al., 2009; Banks et al., 2010; Lai et al., 2013). 
One micro-dystrophin was used in a clinical trial that reported no recombinant dystrophin 
expression (Mendell, 2010) but improved constructs are now in the clinical trial pipeline. 
Another genetic approach involves restoring the reading frame of DMD transcripts 
carrying deletions using exon-skipping technologies of antisense oligonucleotides or 
phosphorodiamidate morpholino oligomers (van Deutekom et al., 2007; Aartsma-Rus et 
al., 2009; Kinali et al., 2009). Like gene therapy constructs, exon-skipping produces an 
internally truncated but partially functional dystrophin and both approaches aim to yield a 
Becker-like phenotype in DMD patients. The exon-skipping drug eteplirsen was recently 
approved by the FDA to treat patients with out-of-frame deletions corrected by exon 51 
skipping (Aartsma-Rus and Krieg, 2017). An additional genetic approach is “read-
through” drugs that suppress nonsense mutations which result in premature codons in 
dystrophin transcripts. The read-through drug ataluren was used in a clinical trial and 
was shown to be safe but did not show clinical efficacy (Bushby et al., 2014). Other 
read-through drugs have been developed and are moving into clinical trials (Karijolich 
and Yu, 2014). 
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With the advancement of gene editing technologies, recent studies have applied 
the CRISPR/Cas9 gene editing system to correct DMD gene mutations (reviewed in 
Hotta, 2015). Proposed CRISPR/Cas9 therapeutic approaches include transplantation of 
gene edited human induced pluripotent stem cells (hIPSCs) as well as AAV delivery of 
Cas9 and guide RNAs (gRNAs). Initial studies demonstrating proof of concept showed 
partial gene editing and dystrophin restoration in mdx mice and DMD patient myoblasts 
(Long et al., 2014; Ousterout et al., 2015). CRISPR/Cas9-mediated deletion of the DMD 
gene in hiPSCs carrying mutations surrounding exons 44 and 51 demonstrated 
expression of frame-corrected dystrophin and restoration of DGC components in hiPSC-
derived cardiomyocytes and myotubes (Young et al., 2016).   Multiple groups utilizing 
AAV mediated delivery of Cas9 and gRNAs in mdx mice have shown dystrophin protein 
restoration to varying degrees and improvement in the dystrophy phenotype (Xu et al., 
2016; Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016; Bengtsson et al., 
2017). While still in pre-clinical stages, CRISPR/Cas9-mediated correction of the DMD 
gene is a promising therapeutic strategy and in the case of AAV delivery, could establish 
a more permanent correction.  
 Utrophin replacement and upregulation therapies have been in development to 
compensate for the absence of dystrophin in DMD. AAV-delivery of a micro-utrophin and 
TAT-mediated protein transduction of full-length or micro-utrophins in mdx mice resulted 
in improvement of muscle function, demonstrating that utrophin can functionally 
substitute for dystrophin (Odom et al., 2008; Sonnemann et al., 2009; Call et al., 2011). 
Additionally, pharmacologic upregulation of endogenous utrophin has shown efficacy in 
mdx mice and the utrophin modulator drug SMT C1100 is currently in clinical trial 
(Tinsley et al., 2011; Ricotti et al., 2016).  Other therapy approaches of note include 
stimulation of muscle regeneration (Campbell et al., 2016), sarcolemmal stabilization 
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(Heller et al., 2015),  and inhibition of inflammatory and fibrosis pathways (Heier et al., 
2013; Bodanovsky et al., 2014).  
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Biophysical Characterization of Dystrophin and Utrophin 
There is a significant body of research that has focused on understanding the 
thermodynamic properties of dystrophin, particularly of the spectrin-like repeats in the 
central rod domain because of their unique sequence and structure compared to other 
spectrin repeats (Nicolas et al., 2014a) and because of their unclear functional 
significance (Legardinier et al., 2008). A meta-analysis of literature reports on the 
thermodynamic stability of dystrophin fragments, repeats, and deletion constructs using 
circular dichroism melting temperature as a common parameter is summarized in Figure 
1.4 (Henderson et al., 2010, 2011; Bhasin et al., 2005b; Legardinier et al., 2008, 2009b; 
Mirza et al., 2010; Singh et al., 2010; Ruszczak et al., 2009; Krieger et al., 2010a; Sahni 
et al., 2012). From this meta-analysis, it is evident that there exists substantial 
heterogeneity among spectrin-like repeats of dystrophin. It also demonstrates that the 
stability of tandem repeat fragments does not necessarily reflect the stability of the 
individual repeats that compose them and that stability is context dependent. Despite 
this heterogeneity, full-length dystrophin appears to behave as a single unit as 
evidenced by its cooperative unfolding during thermal denaturation (Henderson et al., 
2010), a property that is likely important for dystrophin’s function. 
Similar thermodynamic analyses of disease-causing missense mutations in the 
N-terminal actin binding domain and internal deletions have shown increased instability 
and insolubility in vitro (Singh et al., 2010; Henderson et al., 2010, 2011), suggesting 
that dystrophin is sensitive to sequence mutations and deletions. In contrast, utrophin 
exhibits remarkably consistent stability regardless of terminal sequence truncation or 
internal deletion (Henderson et al., 2011). Whether differences in the in vitro 
thermodynamic properties of dystrophin and utrophin impact their stability and function in 
vivo is still unclear but there is evidence that the instability of disease-causing missense 
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mutations in vitro inversely correlates with expression levels of missense mutant proteins 
in cultured myoblasts (Talsness et al., 2015).  
In conjunction with biophysical characterization, there have been efforts to 
evaluate the mechanical behavior of dystrophin given its proposed role as a molecular 
shock absorber. The mechanical stability of proteins differs from thermodynamic stability 
in that the free energy required for unfolding is dependent on spatial distribution (Rief et 
al., 1999). Forced mechanical unfolding data as measured by atomic force microscopy 
for dystrophin central rod domain fragments revealed mechanical properties similar to 
those measured for spectrin, a cytoskeletal scaffolding protein required for plasma 
membrane integrity (Rief et al., 1999; Law et al., 2003b; a; Bhasin et al., 2005b; Krieger 
et al., 2010a). Since dystrophin fragments display considerable heterogeneity in 
thermodynamic stability compared to the full-length protein, it would be important to 
mechanically characterize full-length dystrophin as well as utrophin in order to compare 
with established biophysical characterization.  
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The mdx mouse model of DMD 
Experiments in animal models of DMD have been critical for therapy 
development and for substantiating hypotheses about dystrophin function emerging from 
in vitro studies. The most widely used mouse model for DMD is the naturally occurring 
mdx mouse (named for X-chromosome linked muscular dystrophy) that was first 
discovered in 1984 (Bulfield et al., 1984). Thus, the muscular dystrophy phenotypes of 
the mdx mouse have been well documented. 
At the molecular level, mdx mice have a nonsense mutation in exon 23 of the 
DMD gene, rendering it a dystrophin-deficient mouse and resulting in the reduction of 
other DGC components at the sarcolemma (Hoffman et al., 1987; Sicinski et al., 1989; 
Ohlendieck and Campbell, 1991). The histopathology of mdx skeletal muscle is 
consistent with what is reported in patients, showing increases in central nucleation, 
indicating muscle degeneration and regeneration, and decreases in fiber size (Briguet et 
al., 2004). Mdx mice show elevated serum creatine kinase levels and increased uptake 
of cell-impermeable dyes in skeletal muscle, suggesting a loss of sarcolemmal integrity 
(Bulfield et al., 1984; Moens et al., 1993; Consolino and Brooks, 2004).  Physiologically, 
mdx mice have reductions in grip strength and whole body tension (Connolly et al., 
2001), show marked inactivity after mild exercise (Kobayashi et al., 2008), and 
demonstrate eccentric contraction-induced force loss both in vitro and in vivo (Petrof et 
al., 1993; Consolino and Brooks, 2004).  
Even though mdx mice display hallmark signs of DMD muscle pathology 
compared to wild-type mice, the phenotype is considerably milder than what is seen in 
DMD patients (Tanabe et al., 1986). A possible explanation for the milder phenotype is 
that mice compensate for lack of dystrophin through upregulation of utrophin 
(Matsumura et al., 1992; Dowling et al., 2002), a hypothesis supported by the more 
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severe phenotype seen in utrophin-deficient mdx mice and the rescue of dystrophic 
phenotype upon utrophin overexpression (Grady et al., 1997; Deconinck et al., 1997; 
Tinsley et al., 1998).  Another possible explanation is that the mice have an enhanced 
muscle regeneration response that may be dependent on the murine genetic 
background (Fukada et al., 2010). Mdx mice bred onto a background with decreased 
regenerative capacity (DBA/2) exhibit a more severe phenotype (Fukada et al., 2010; 
Rodrigues et al., 2016). Furthermore, mdx mice lacking MyoD, a transcription factor 
required for muscle regeneration, have a marked increase in dystrophic pathology 
(Megeney et al., 1996). Despite its imperfections as a model of DMD, the mdx mouse 
has been a critical resource in elucidating mechanisms of dystrophy and in the 
development of therapies that are now approved or in clinical trial. 
Additional animal models of DMD have been identified or developed to address 
the limitations of the mdx mouse. Mouse lines with different mutation types, modulated 
levels of dystrophin, or on different backgrounds have been particularly valuable 
(McGreevy et al., 2015). Non-mammalian animal models of dystrophin deficiency include 
C. elegans (Chamberlain and Benian, 2000), drosophila (Lloyd and Taylor, 2010), and 
zebrafish (Kunkel et al., 2006). Larger mammalian models that have been identified as 
naturally occurring are a golden retriever muscular dystrophy (GRMD) model that has 
become a standard for pre-clinical testing for DMD therapies (Valentine et al., 1986; 
Cooper et al., 1988; Kornegay et al., 2012) and a BMD porcine model with a missense 
mutation (Nonneman et al., 2012). 
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Questions Addressed by this Thesis 
Our lab has previously demonstrated that the thermal stability of dystrophin is 
sensitive to disease-causing point mutations and internal deletions (Henderson et al., 
2010, 2011). Several therapeutic strategies to treat DMD utilize internally deleted 
dystrophins, including the recently FDA approved exon-skipping drug, eteplirsen 
(Aartsma-Rus and Krieg, 2017), and viral delivery of therapeutic micro-dystrophins 
(Sakamoto et al., 2002; Wang et al., 2000). Thus my thesis seeks to answer the 
question: “How do deletions present in therapeutically relevant, internally 
truncated dystrophins affect in vitro protein stability?’  
My analysis of thermal stablity in vitro showed that micro-dystrophin gene 
therapy constructs are significantly less stable than full-length dystrophin whereas the 
exon-skipped dystrophins have stability profiles congruent with full-length dystrophin 
(McCourt et al., 2015).  My in vitro thermal studies also reinforce the need to better 
understand how differences in protein stability in vitro translate to therapeutic efficacy in 
vivo. A recent study in cultured myoblasts suggested that dystrophin proteins bearing 
DMD or BMD-causing missense mutations, the mutant proteins are targeted to the 
proteasome for degradation resulting in reduced steady state dystrophin protein levels 
(Talsness et al., 2015). Using the cell culture models and novel transgenic mice 
expressing missense dystrophins, we answered the questions: How are missense 
dystrophin proteins regulated in murine models of DMD and BMD missense 
mutants?  
While dystrophin stability is sensitive to missense mutations and internal 
deletions, the fetal homologue of dystrophin, utrophin, maintains stability upon terminal 
or internal deletions (Henderson et al., 2011). However, differences in thermodynamic 
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properties between dystrophin and utrophin do not address their proposed function as 
molecular springs to mechanically stabilize the muscle membrane during muscle 
contraction (Ervasti, 2007). Our aim is to use atomic force microscopy to address the 
question: What are the mechanical properties of full-length utrophin and 
functionally relevant utrophin fragments? 
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Figures 
 
 
 
 
 
Figure 1.1: Frequency of DMD/BMD mutation types. Data compiled from the Treat-
NMD DMD Global Database (Bladen et al., 2015).  
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Figure 1.2: Dystrophin and utrophin protein interacting domains. NT – amino 
terminus; CR – cysteine rich domain; CT – carboxy terminus; ovals – spectrin-like 
repeats; diamonds – unstructured “hinge” regions; ABD – actin binding domain; MBD – 
membrane binding domain; nNOS – neuronal nitric oxide synthase; MTBD – microtubule 
binding domain; DgBD – dystroglycan binding domain; AnkB/G – ankyrin B/G; Syn BD – 
syntrophin binding domain; DB BD – dystrobrevin binding domain.  
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Figure 1.3: The Dystrophin-Glycoprotein Complex. Diagram of the core members of 
the dystrophin-glycoprotein complex at the sarcolemma. On the inside of the cell are 
dystrophin, syntrophins, and α-dystrobrevin-2. Spanning the membrane are β-
dystroglycan, sarcospan, α-, β-, γ-, and δ-sarcoglycan. On the extracellular side are α-
dystroglycan, and laminin-2.  
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Figure 1.4: Meta-analysis of melting temperatures of dystrophin fragments (A) and 
exon-skipped constructs (B). Individual spectrin-type repeats are represented by 
rounded squares, hinge regions represented by diamonds. White boxes represent full-
length dystrophin with a melting temperature of 59.6°C. Blue and red shaded boxes 
indicate repeats/fragments that had melting temperatures below or above 59.6°C, 
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respectively; purple shaded boxes indicate constructs that had multiple melting 
temperatures; orange bordered boxes indicate constructs that were not expressible.  
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Synopsis 
The X-linked recessive disease Duchenne muscular dystrophy (DMD) is caused by 
mutations in the gene encoding the protein dystrophin. Despite its large size, dystrophin 
is a highly stable protein, demonstrating cooperative unfolding during thermal 
denaturation as monitored by circular dichroism spectroscopy. In contrast, internal 
sequence deletions have been associated with a loss of the cooperative unfolding and 
cause in vitro protein aggregation. Several emerging therapy options for DMD utilize 
internally deleted micro-dystrophins and multi-exon skipped dystrophins that produce 
partially functional proteins but the stability of such internally-truncated proteins has not 
been investigated. In this study, we analyzed the in vitro stability of human dystrophin 
constructs skipped around exon 45 or exon 51, several dystrophin gene therapy 
constructs, as well as human full-length and micro-utrophin. Our results reveal that not 
all gene therapy constructs display stabilities consistent with full-length human 
dystrophin. However, all dystrophins skipped in-frame around exon 45 or exon 51 show 
stability profiles congruent with intact human dystrophin. Similar to previous studies of 
mouse proteins, full-length human utrophin also displays stability similar to human 
dystrophin and does not appear to be affected by a large internal deletion. Our results 
suggest that the in vitro stability of human dystrophin is less sensitive to smaller 
deletions at natural exon boundaries than larger, more complex deletions present in 
some gene therapy constructs.  
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Introduction 
The X-linked disease Duchenne muscular dystrophy (DMD) is caused by 
mutations in the gene encoding the protein dystrophin (Hoffman et al., 1987). Mutations 
causing this disease are variable with 65% of DMD patients harboring deletions which 
span exons, 5-15% having duplications, and the remaining populations having either 
point mutations or deep intronic deletions (Muntoni et al., 2003). Becker muscular 
dystrophy (BMD) is a milder allelic form of dystrophy typically caused by in-frame gene 
deletions that maintain reading frame, but presumably cause disease through diminished 
abundance or functionality (Koenig et al., 1989). 
 The dystrophin protein is a critical molecular component of the dystrophin-
glycoprotein complex (DGC) that functions to maintain skeletal muscle integrity during 
contraction (Rybakova and Ervasti, 1997; Ervasti, 2007). Dystrophin provides a 
structural link between the sub-sarcolemmal cytoskeleton and the extracellular matrix 
through interactions with actin (Rybakova et al., 1996, 2000), intermediate filaments 
(Stone et al., 2005; Bhosle et al., 2006; Rezniczek et al., 2007), microtubules (Prins et 
al., 2009; Belanto et al., 2014) and the membrane-associated dystroglycan complex 
(Jung et al., 1995; Ishikawa-Sakurai et al., 2004). The observation that milder BMD 
patients harbor deletions in the central rod domain suggests that dystrophin can tolerate 
such deletions to some degree and that the central rod domain is less critical to the 
function of dystrophin. 
Two avenues of therapeutic research have focused on producing internally 
truncated, Becker-like dystrophins in DMD patients. Exon-skipping approaches aim to 
restore the reading frame of mutated DMD transcripts using antisense oligonucleotides 
(ASOs) or phosphorodiamidate morpholino oligomers (PMOs), producing an internally 
truncated but partially functional protein (van Deutekom et al., 2007; Aartsma-Rus et al., 
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2009; Kinali et al., 2009). Alternatively, adeno-associated viral (AAV) gene therapy is 
under active investigation to express miniaturized dystrophin constructs in DMD patients 
due to the large size of the dystrophin gene and the limited capacity of AAV 
vectors(Harper et al., 2002; Sakamoto et al., 2002; Wang et al., 2000).  
The stability of the corresponding proteins produced from dystrophin exon 
skipping or AAV-mediated delivery of micro-dystrophins is unknown and may be an 
important factor to maximize therapeutic efficacy.  Previous in vitro work has 
demonstrated that the stability of mouse dystrophin was sensitive to disease-causing 
missense mutations and internal deletion (Henderson et al., 2010, 2011), raising the 
question of whether the stabilities of micro-dystrophins or exon-skipped dystrophins 
relevant to DMD therapies might also be compromised. In contrast, the stability of 
mouse utrophin, a fetal homologue of dystrophin, was insensitive to both terminal and 
internal deletion (Henderson et al., 2011).  
Here, we expressed and purified five dystrophins skipped around exon 45 or 51 
with an exon 43-skipped control, five recombinant dystrophin gene therapy constructs, 
and two utrophin constructs. The selected constructs represent the leading therapy 
approaches that have been shown to ameliorate the dystrophic phenotype in mdx mice 
with transition to clinical trials underway (Wang et al., 2000; Sakamoto et al., 2002; Lu et 
al., 2005; Alter et al., 2006; Odom et al., 2008; Sonnemann et al., 2009; Banks et al., 
2010; Call et al., 2011). In the current study, all constructs were expressed from human 
sequences, as opposed to the mouse constructs used previously (Henderson et al., 
2010, 2011). Our biophysical analysis revealed that the dystrophin gene therapy 
constructs exhibited more variable stabilities in vitro while exon-skipped dystrophin 
constructs showed stabilities not different from full-length dystrophin. Consistent with 
previous mouse studies, utrophin maintained stability despite internal deletion.  
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Methods 
Cloning 
Full-length human dystrophin was obtained from the DNASU vector repository in the 
pE223 Gateway entry vector. Human utrophin and micro-utrophin were cloned from 
HEK293 cells into the pENTR/D-TOPO vector (Invitrogen™) and sequence verified. An 
8-amino acid FLAG-tag (DYKDDDDK) was added to the N-terminus of both human 
dystrophin and utrophin constructs for use in purification. All human dystrophin deletion 
constructs were PCR amplified using primers designed around adjacent exons, repeats, 
or domains for the desired deletion based on reported repeat and domain 
boundaries(Winder et al., 1995). The PCR products were circularized using T4 
polynucleotide kinase and T4 DNA ligase (New England BioLabs) and sequence 
verified. Using the Gateway Recombination system (Life Technologies), the deletion 
constructs were recombined into the pDEST8 destination vector and subsequently 
transformed into DH10Bac competent E. Coli and purified according to the 
manufacturer’s protocol. 
Protein expression and purification 
Sf9 insect cells were maintained at 1 x 106 cells/mL in Sf-900™ II SFM (Life 
Technologies). Purified Baculovirus was transfected using Cellfectin® II (Life 
Technologies) and high-titer viral stocks were generated through successive infections 
of Sf9 cells in 3.5 cm plates (P0), 10 cm plates (P1), and 250 mL of 1 x 106 cells/mL 
suspended cells (P2). Ten mL of P2 virus were used to infect 250 mL of 1 x 106 cells/mL 
and cultured for 72-hour post-infection to maximize protein expression. Infected cells 
were centrifuged at 1,000 x g for 3 minutes and re-suspended in phosphate buffered 
saline (PBS) containing a cocktail of protease inhibitors [100nM Aprotinin, 10mg/mL E-
64, 10μM Leupeptin, 1mM PMSF, 1μg/mL Pepstatin]. Cells were lysed by sonication, 5 
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bursts of 30 seconds using a BioLogics Ultrasonic Homogenizer set at 30% power. The 
lysate was centrifuged at 14,000 x g for 10 min at 4ºC and the supernatant applied to an 
anti-FLAG M2 agarose column (Sigma Aldrich). The column was washed with >10 
column volumes of PBS and bound protein eluted with PBS containing protease 
inhibitors and 100µg/mL FLAG peptide. After dialysis overnight in 2L of PBS at pH 7.5, 
the purified protein was concentrated using the Amicon Centrifugal Filter unit 
(UFC801024) and protein concentration was determined using A280 and extinction 
coefficients calculated from the amino acid compositions for each construct. 
Concentrated proteins were run on a 3-12% SDS polyacrylamide gradient gel and run at 
150V for 1 hour. Gels were stained with Coomassie blue stain and visualized using 
Licor’s Odyssey® Infrared Imaging System. 
Tandem purification of full-length human dystrophin 
To optimize the purification of full-length human dystrophin, a Twin-Strep-tag® (IBA), 
with amino acid sequence SA-WSHPQFEK(GGGS)2GGSAWSHPQFEK, was cloned 
onto the C-terminus of pE223 dystrophin in addition to the N-terminal FLAG-tag. The 
dual-tagged dystrophin was then recombined into the pDEST8 expression vector and 
expressed in the Sf9 baculovirus system as described above. The cell lysate was 
applied to a Strep-Tactin ® Superflow ® high capacity resin (IBA), eluted with 100 mM 
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 2 mM desthiobiotin, pH 8, and the eluent 
immediately applied to an anti-FLAG M2 agarose column as described above. 
Western Blotting 
Purification fractions from the tandem purification were run on a 3-12% SDS 
polyacrylamide gradient gel at 150V for 1 hour. The gel was transferred onto a 
polyvinylidene difluoride (PVDF) membrane at 100V for 1 hour. The PVDF membrane 
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was blocked using 5% milk in 1X PBS, 0.1% Tween and blotted using mouse 
monoclonal anti-FLAG M2 (Sigma Aldrich, F1804) and rabbit polyclonal anti-Strep-tag II 
(Abcam, ab76949) antibodies at 1:1000 dilution. The blot was visualized using anti-
mouse DyLight™ 800 (green channel) and anti-rabbit DyLight™ 680 (red channel) 
conjugate antibodies in Licor’s Odyssey® Infrared Imaging System. 
High-speed sedimentation 
Each purified protein was diluted to 0.3 mg/mL (for exon 51 skipped dystrophins) or 0.5 
mg/mL (for all other proteins) with PBS in a final volume of 120 µL and 60 µL was 
immediately aliquoted into 12 µL 6X LSB to prepare a “total” fraction. The remaining 60 
µL was centrifuged at 100,000 x g for 30 minutes at 4ºC. The supernatant was 
transferred into 12 µL 6X LSB and the pellet re-suspended in 72 µL of 1X LSB. Triplicate 
fractions were run on a 3-12% gradient polyacrylamide gel at 150V for 1 hour and 
stained with Coomassie blue stain. Gels were scanned using Licor’s Odyssey® Infrared 
Imaging System and band density calculated with Odyssey Software v2.1. Full-length 
human dystrophin was used as a control at both 0.3 mg/mL and 0.5 mg/mL 
concentrations and did not show any significant difference in percent aggregation 
between the different concentrations (17.6% ± 7.39 and 17.4% ± 7.30, respectively). 
Circular dichroism 
Each purified protein was centrifuged at 14,000 x g for 10 minutes at 4ºC and the 
supernatant diluted to 0.5 mg/mL (for gene therapy and utrophin proteins) or 0.3 mg/mL 
(for exon-skipped and full-length dystrophins) using PBS. Absorption spectra were 
acquired with a Jasco J-815 spectropolarimeter, initially at 20°C as controlled by a 
Peltier device, from 200 to 260nm wavelength. Spectra were then acquired at 1°C 
temperature intervals from 20-90°C and the characteristic ellipticity at alpha-helical 
wavelength (θ222) recorded. Molar ellipticity, [θ], was calculated using the following 
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equation: [θ] = θ / (10 x c x l) where c is the molar concentration of the sample (mole/L) 
and l is the path-length in cm. Molar ellipticity (with units of degrees, cm squared per 
decimole) was plotted against wavelength for the circular dichroism (CD) spectra. 
Ellipticity at 222nm (θ222) was normalized, plotted against temperature, and fit by 
regression analysis in Sigma Plot (Systat Software, Inc.) using equations for two state or 
three state unfolding (Legardinier et al., 2009a). 
Differential scanning fluorimetry 
Our method closely followed that described by Niesen et al(Niesen et al., 2007). Briefly, 
the fluorescent dye SYPRO Orange (Life Technologies™ #S6650) was incubated at a 
ratio of 1:1000 (w/w) with 0.5 mg/mL (or 0.3 mg/mL for exon-skipped proteins) of purified 
protein in PBS. The dye/protein solution was aliquoted into 50µL-technical triplicates and 
an emission of 610nm was measured in a real time PCR instrument (iCycler, Bio-Rad) 
as the temperature was increased from 20° to 90°C at 1°C temperature intervals. The 
fluorescence was normalized from 0 to 1, plotted against temperature, and fit by 
regression analysis in Sigma Plot (Systat Software, Inc.) using an equation for a two 
state unfolding model(Legardinier et al., 2009a). 
Statistical analysis 
Data for percentage aggregation and melting temperatures of single transition melt 
curves from CD and differential scanning fluorimetry (DSF) were analyzed using a one-
way analysis of variance (ANOVA) with a Tukey’s post hoc test in Prism software 
(GraphPad), all compared to full-length human dystrophin. 
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Results 
Basis for Choice of Recombinant Proteins and Gel Analysis 
The choice of constructs to analyze was based on current models for exon-
skipping and gene therapy in pre-clinical testing and clinical studies (Figure 2.1). The 
exon 45-skipped and exon-51 skipped dystrophins were analyzed because they could 
potentially treat 8% and 13% of DMD patients, respectively (Aartsma-Rus et al., 2009) 
and ASO and morpholino drugs targeting these exons are currently in clinical trials 
(Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy, A Study of 
the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & 
Canadian Subjects). Therefore, we expressed a subset of exon-45 and exon-51 skipped 
human dystrophins, ∆ex44-45, ∆ex45-46, ∆ex45-51, ∆ex51-52, ∆ex51-63, as well as 
∆ex43-44, a control deletion that has been previously speculated to cause decreased 
stability (Ruszczak et al., 2009). While we initially attempted to generate a larger array of 
exon-51 skipped constructs, we analyzed the three (∆ex45-51, ∆ex51-52, and ∆ex51-63) 
that yielded products in the first stages of cloning. 
The gene therapy constructs µH2 hDys and µH3 hDys contain spectrin-like 
repeats (SLRs) 1-3 and 24 with hinge 2 or hinge 3, respectively. These constructs have 
been shown to ameliorate the dystrophic phenotype in mdx mice (Banks et al., 2010) 
and µH2 also showed significant expression with muscle improvement in the GRMD dog 
model of DMD (Wang et al., 2007, 2012). The ∆3990 hDys construct corresponds to the 
AAV-delivered micro-dystrophin used in a clinical trial that reported minimal recombinant 
dystrophin expression associated with a strong immune response to dystrophin (Wang 
et al., 2000; Mendell, 2010). Constructs ∆H2-R15/∆CT hDys and ∆R3-15/18-23/∆CT 
hDys are miniaturized dystrophins that retain SLRs 16 and 17 necessary for 
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sarcolemmal localization of neuronal nitric oxide synthase (nNOS) (Lai et al., 2009, 
2012). Full-length human utrophin and a micro-utrophin (µH2 hUtr, homologous to µH2 
hDys) correspond to constructs that are under investigation for gene, cell, and protein-
based therapies (Odom et al., 2008; Sonnemann et al., 2009; Call et al., 2011; Filareto 
et al., 2013). 
While gel analysis of the FLAG affinity-purified recombinant proteins revealed a 
predominant band of the expected molecular weight for each purified dystrophin gene 
therapy and utrophin constructs, full-length and exon skipped human dystrophins 
exhibited a near-stoichiometric contaminating fragment at ~230 kDa (Figure 2.2A) that 
was not previously observed in preparations of full length mouse dystrophin (Henderson 
et al., 2010) and was not present in gene therapy or utrophin preparations (Figure 2.2A). 
To identify the contaminating fragment, we generated and expressed a dual-tagged, full-
length human dystrophin containing a C-terminal Twin-Strep-tag® (IBA) in addition to the 
N-terminal FLAG-tag. Western blot analysis after tandem affinity purification of the 
dually-tagged dystrophin revealed that the near-stoichiometric, ~230 kDa contaminating 
fragment present in the FLAG affinity-purified samples was an N-terminal fragment 
(green band, Figure 2.2B) and was mostly likely caused by a cleavage from a protease 
in our expression system. The cleavage event was further confirmed by the presence of 
the corresponding C-terminal fragment in the load and elution fractions of the Strep-tag 
purification (red band, Figure 2.2B). The absence of the contaminating N-terminal 
fragment in constructs with deletions preceding repeat 16 combined with its presence in 
constructs with deletions after repeat 16 suggests that the proteolytic cleavage site 
resides within repeat 14 or 15, which would yield the predicted N-terminal fragment of 
~230 kDa. While the tandem purification was successful in identifying the contaminating 
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fragments and a more purified full-length dystrophin was recovered (yellow band), the 
resulting yield was not sufficient to support the planned biochemical or biophysical 
analyses. Therefore, single FLAG affinity-purified proteins were used in all subsequent 
analyses. 
Protein Aggregation 
High-speed sedimentation is a facile in vitro technique to quantify aggregation of 
purified proteins. Full-length human dystrophin exhibited 17.6% aggregation (Figure 2.3, 
Table 2.1), which is similar to the 14% aggregation previously reported for full-length 
mouse dystrophin(Henderson et al., 2010). Exon-skipped dystrophin proteins did not 
show significant increases in aggregation relative to full-length human dystrophin, 
however ∆ex43-44 showed a significant decrease in aggregation (gray bars, Figure 2.3). 
Four of the five gene therapy proteins showed a significant increase, with percent 
aggregation ranging from 31.7 to 44.4% (white bars, Figure 2.3, Table 2.1). Interestingly, 
the ∆3990 protein was the only gene therapy construct that exhibited protein aggregation 
congruent with full-length dystrophin. Similar to the exon-skipped dystrophins, utrophin 
and micro-utrophin did not vary significantly from full-length dystrophin aggregation 
(lined bars, Figure 2.3). 
Assessment of Secondary Structure Unfolding 
To assess secondary structure and protein unfolding, we analyzed the purified 
proteins by circular dichroism (CD) spectroscopy. All of the constructs exhibited CD 
spectra characteristic of proteins with high alpha-helical content and minima at 208 and 
222 nm (Figure 2.4A-C).  As the temperature was increased, loss of secondary structure 
(or unfolding) was monitored at 222nm to generate melt curves (Figure 2.4D-F) with a 
calculated melting temperature or temperatures (Table 2.1). Full-length human 
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dystrophin exhibited a single transition melt curve with a melting temperature of 48.1°C 
(Table 2.1, Figure 2.4), which is in contrast to the 59.6°C melting temperature reported 
for full-length mouse dystrophin (Henderson et al., 2010). Upon closer inspection of the 
melt curves from the previous report, it is apparent that full-length mouse dystrophin 
exhibited an additional melting transition similar to the dystrophin isoform DP260 
(Henderson et al., 2011), a property that is absent in CD melt curves of human 
dystrophin. Exon-skipped dystrophins exhibited single transitions all with comparable 
melting temperatures to full-length dystrophin (Figure 2.4D, Table 2.1). Two of the gene 
therapy constructs, ∆3990 and ∆R3-15/18-23/∆CT, also displayed a single transition but 
∆3990 had a significantly higher melting temperature of 56.1°C. However, the other gene 
therapy constructs displayed a second transition with two calculated melting 
temperatures ranging from 47° to 85°C (Figure 2.4E, Table 2.1). This indicates that the 
protein is either not unfolding cooperatively, or is composed of two populations of folded 
and unfolded states. Full-length human utrophin and µH2 hUtr displayed single transition 
melt curves with melting temperatures of 46.2 and 47°C, respectively (Figure 2.4F, Table 
2.1). These values are not significantly different from full-length dystrophin and are 
consistent with previously reported melting temperatures for mouse full-length and 
micro-mouse utrophins (Henderson et al., 2011). 
Assessment of Tertiary Structure Unfolding 
Differential scanning fluorimetry (DSF) utilizes a fluorescent dye that increases its 
fluorescence emission upon binding to hydrophobic moieties in proteins, which become 
more exposed and accessible as a protein unfolds during thermal denaturation (Niesen 
et al., 2007). Like CD, DSF can be used to obtain protein melt curves, but unlike CD, the 
signal measured reflects changes in tertiary structure rather than secondary structure. 
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By DSF analysis, full-length human dystrophin displayed a melt curve with a single 
transition at 45.7°C (Figure 2.5). This temperature was lower than that seen in CD, 
consistent with the concept that tertiary structure will be lost before secondary structure. 
Exon-skipped dystrophins displayed single transitions with similar melting temperatures 
to full-length dystrophin ranging from 43.7° to 48.1°C (Figure 2.5A, Table 2.1). In 
contrast to the CD data, all of the gene therapy constructs exhibited single transitions 
with melting temperatures ranging from 45.8° to 50.4°C (Figure 2.5B, Table 2.1). Both 
∆3990 and ∆H2-R15/∆CT hDys had significantly right-shifted melt curves from full-length 
dystrophin with melting temperatures of 50.4° and 49.8°C, respectively. Full-length and 
micro-utrophin both show a left-shifted melt curve with melting temperatures of 43.4° and 
42.9°C, respectively, but, like exon-skipped dystrophins, these values are not 
significantly different from full-length dystrophin (Figure 2.5C, Table 2.1). 
  34 
Discussion 
In this study, we have analyzed the biophysical properties of several 
therapeutically relevant, internally truncated dystrophins and utrophins. Therapies that 
produce internally deleted dystrophins are based on observations that patients with the 
milder BMD can harbor large deletions in the central rod domain. In addition to 
conferring elasticity or flexibility to dystrophin (Koenig and Kunkel, 1990; Ervasti, 2007; 
Saadat et al., 2006), it is known that the central rod domain encodes a second actin 
binding domain (Rybakova et al., 1996; Amann et al., 1998; Warner et al., 2002), as well 
as domains for localizing nNOS to the sarcolemma (Lai et al., 2009, 2012), for in vitro 
binding to phospholipids (Legardinier et al., 2008, 2009b), intermediate filaments (Bhosle 
et al., 2006), and microtubules (Prins et al., 2009; Belanto et al., 2014). 
The biophysical properties of individual and tandem repeats of the rod domain 
have been extensively investigated and these findings demonstrate a wide range of 
stabilities (Mirza et al., 2010; Legardinier et al., 2008, 2009b; Bhasin et al., 2005b), 
whereas full-length dystrophin has remarkable cooperative stability (Henderson et al., 
2010). Additionally, there is evidence that certain internal deletions of the central rod 
domain are associated with increased protein aggregation and instability (Henderson et 
al., 2011). Together, these studies suggest that the stability of individual or tandem 
repeat fragments does not necessarily reflect that of larger fragments or full-length 
dystrophin proteins and that protein stability of individual regions within dystrophin is 
context dependent. 
Several groups have investigated the biophysical consequences of exon-skipping 
on dystrophin fragments within the central rod domain, particularly those spanning exons 
43 to 51 (Ruszczak et al., 2009; Krieger et al., 2010b; Sahni et al., 2012; Nicolas et al., 
2012). For constructs skipping exon 51, they concluded that some protein fragments are 
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more stable than others. Our results, however, suggest that for dystrophins skipped 
around exon 51, there is little measureable change in stability in vitro between exon-
skipped proteins and full-length human dystrophin. This conclusion is consistent with the 
conclusions of a recent report that assessed the structural differences and stability 
profiles of human dystrophin fragments with deletions around exon 51 (Nicolas et al., 
2014b). They found that while there were marked structural differences between the 
different deletion fragments, the stability was not significantly affected. 
For the common, out-of-frame deletion of exon 45 (∆45) in patients, exon-
skipping therapies are being designed to either delete exon 44 (∆ex44-45) or exon 46 
(∆ex45-46) to correct the reading frame. Based on another recent report, it was 
speculated that the ∆ex45-46 dystrophin protein might be highly unstable because this 
in-frame deletion is associated with the more severe DMD phenotype in patients (Findlay 
et al., 2015), and therefore a ∆ex44-45 skipping strategy would be more beneficial. 
However, based on our in vitro data, there does not appear to be any significant 
difference in stability between ∆ex44-45 and ∆ex45-46 and full-length dystrophin 
proteins. These different conclusions from the clinical and in vitro studies indicate that 
the source of pathogenesis from the exon 45-46 deletion may not depend on the stability 
of the resulting protein, but perhaps is caused by a regulatory or functional perturbation. 
Interestingly, all of the exon-skipped dystrophins evaluated in our study displayed in vitro 
stabilities congruent with full-length dystrophin, including the ∆ex43-44 protein that 
exhibited decreased stability when previously evaluated in the context of a smaller 
recombinant fragment encompassing SLRs 16-18 (Ruszczak et al., 2009). Because 
dystrophy-causing missense mutations also cause less dramatic instability in full-length 
dystrophin compared to small fragments (Henderson et al., 2010; Singh et al., 2010), it 
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seems possible that long-range and cooperative intra-protein communication may serve 
to buffer dystrophin against the destabilizing effects of sequence changes and deletions. 
We also expressed internally deleted human micro-dystrophins that are currently 
under investigation for gene therapy. We showed that several of these constructs have 
significantly different stability compared to the full-length human dystrophin protein. Both 
micro-dystrophins µH2, hDys, and µH3 hDys displayed increased aggregation and 
additional melting transitions upon secondary structure unfolding. One of the 
sarcolemmal nNOS-localizing constructs, ∆H2-R15/∆CT hDys, displayed similar 
behavior. Interestingly, the more truncated nNOS-localizing construct, ∆R3-15/18-
23/∆CT, exhibited a single melting transition similar to full-length dystrophin but also 
increased aggregation. These data suggest that the in vitro stability of dystrophin gene 
therapy constructs may be dependent on the stability of the non-native junction created 
by the internal deletion. The ∆3990 hDys construct was the only gene therapy construct 
that exhibited wild-type aggregation and it displayed significantly increased melting 
temperatures for both CD and DSF, suggesting that the ∆3990 protein is more stable 
than full-length dystrophin. However, a small clinical trial for AAV-mediated delivery of 
the ∆3990 was not successful (Mendell, 2010). 
Utrophin replacement therapies are also currently under investigation, therefore 
we analyzed the stability of full-length human utrophin and a micro-utrophin. A previous 
study demonstrated that mouse utrophin is a highly stable protein that does not appear 
to be sensitive to terminal truncation or internal deletion (Henderson et al., 2011). 
Consistent with these results, our data showed that both full-length and micro-utrophin 
have similar protein aggregation to dystrophin and maintain melting temperatures that 
are not significantly different from full-length human dystrophin. Investigation of utrophin 
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as a dystrophin substitute therapy for DMD (Odom et al., 2008; Sonnemann et al., 2009; 
Call et al., 2011; Filareto et al., 2013) is based on its ability to rescue most phenotypes 
of the mdx mouse when transgenically overexpressed (Tinsley et al., 1998) and also the 
positive correlation between increased utrophin expression with improved prognosis in a 
small cohort of DMD patients (Kleopa et al., 2006). Utrophin maintains some functional 
properties of dystrophin, such as forming an analogous utrophin-glycoprotein complex 
(Matsumura et al., 1992) and binding actin filaments (Rybakova et al., 2006), but lacks 
the ability to localize nNOS to the sarcolemma (Li et al., 2010; Lai et al., 2012) and 
organize the sub-sarcolemmal microtubule lattice (Belanto et al., 2014). While utrophin 
cannot completely substitute for dystrophin in terms of protein-protein interactions, our 
results suggest that utrophin and micro-utrophin proteins are appealing as therapeutic 
targets in terms of protein stability, especially when compared to dystrophin gene 
therapy proteins. 
While the recombinant dystrophin and utrophin proteins used in this study were 
expressed in a eukaryotic cellular environment, their purification and characterization in 
more simple buffers leaves open the possibility that they exhibit unfolding and 
aggregation properties in vitro that are different from how they behave in the complex 
environment of a mammalian muscle cell. It will therefore be important to develop both 
cell and tissue-based model systems to better understand how deletions in dystrophins 
and utrophins affect stability in vivo. 
Our in vitro analysis of the biophysical consequences of internal deletion on 
dystrophin and utrophin suggests that dystrophin stability is context-dependent: relatively 
unaffected by small deletions at natural exon boundaries, but sensitive to larger and 
more complex rearrangements from deletions present in gene therapy constructs. In 
contrast, utrophin maintains uniform stability despite large internal deletion. Moreover, 
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our results also highlight the need to better understand how differences in protein 
stability in vitro translate to therapeutic efficacy in vivo.  
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Figures 
 
 
 
Figure 2.1: Dystrophin and utrophin constructs analyzed. A Diagram of full-length 
human dystrophin (hDys); NT – N-terminus, CR – cysteine-rich domain, CT – C-
terminus, circles – spectrin-like repeats, diamonds – unstructured “hinge” regions, 
ABD1/2 – actin binding domains, nNOS BD – neuronal nitric oxide synthase binding 
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domain, MTBD – microtubule binding domain, DgBD – dystroglycan binding domain, 
Syn BD – syntrophin binding domain, DB BD – dystrobrevin binding domain. B Diagrams 
of exon-skipped human dystrophin constructs analyzed. C Diagrams of gene therapy 
human dystrophins analyzed. D Diagrams of full-length human utrophin (hUtr) and a 
micro-utrophin (µH2 hUtr) analyzed. 
 
  41 
 
 
Figure 2.2: Gel analysis of purified recombinant proteins. A Representative 
Coomassie-stained gels with 5 μg of exon-skipped dystrophins, gene therapy 
dystrophins, and utrophins loaded for comparison. B Western blot of purification 
fractions from tandem purification of dual-tagged full-length human dystrophin with N-
terminal (NT) FLAG-tag (green channel) and C-terminal (CT) Strep-tag (red channel); 
fractions from Strep affinity purification and FLAG affinity purifications: load (L), void (V), 
wash (W), and elute (E).   
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Figure 2.3: Analysis of protein aggregation by high-speed sedimentation. 
Quantification of high-speed sedimentation assay of supernatant (S) and pellet (P) 
fractions where % aggregation = S/(S+P); full-length human dystrophin (hDys) in black 
bar, exon-skipped dystrophins in gray bars, gene therapy dystrophins in white bars, and 
utrophins in lined bars; * p<0.05, ** p< 0.0001 using ANOVA statistical analysis 
compared to full-length human dystrophin.  
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Figure 2.4: Spectra and melt curves obtained by circular dichroism spectroscopy. 
(A-C) Circular dichroism absorption spectra from 200 to 260 nm for exon-skipped 
dystrophins (A), gene therapy constructs (B), and utrophins (C). Molar Ellipticity [θ], with 
units of degrees cm2 per decimole, was calculated as θ / (10 x c x l) where c is the molar 
concentration of the sample (mole/L) and l is the path-length in cm.  (D-F) CD absorption 
spectra monitored at 222nm from 20°C to 90°C for exon-skipped dystrophins (D), gene 
therapy dystrophins (E), and utrophins (F). Melt curves were normalized to θ222 from 0-1 
fraction unfolded and a representative curve plotted. See Table 1 for melting 
temperatures (CD Tm1 and Tm2).  
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Figure 2.5: Melt curves obtained by differential scanning fluorimetry. Differential 
Scanning Fluorimetry (DSF) melt curves for exon-skipped dystrophins (A), gene therapy 
dystrophins (B), and utrophins (C). Fluorescence monitored at 610nm from 20°C to 90°C 
and fluorescence normalized from 0-1 fraction unfolded and a representative curve 
plotted. See Table 2.1 melting temperatures (DSF Tm).  
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Construct Molecular 
Weight (kDa) 
CD Tm1 
(oC) 
CD Tm2 
(oC) 
DSF Tm (oC) % 
Aggregation 
hDys 427 48.1 ± 1.17 - 45.7 ± 2.62 17.6 ± 7.11 
∆ex43-44 414 46.7 ± 0.70 - 44.3 ± 0.35 3.4 ± 0.73* 
∆ex44-45 413 51.7 ± 1.51 - 48.1 ± 1.54 15.7 ± 2.83 
∆ex45-46 414 48.4 ± 2.38 - 46.0 ± 2.60 27.9 ± 5.28 
∆ex45-51 385 47.9 ± 4.07 - 44.6 ± 1.63 10.9 ± 7.00 
∆ex51-52 414 47.2 ± 0.87 - 43.8 ± 0.31 12.9 ± 6.70 
∆ex51-63 351 48.6 ± 3.08 - 43.7 ± 1.15 10.4 ± 7.11 
µH2 139 47.3 ± 1.25 85.1 ± 4.14 46.0 ± 1.28 44.4 ± 10.10** 
µH3 137 49.5 ± 1.78 79.0 ± 2.82 45.8 ± 0.86 31.7 ± 6.72** 
∆3990 154 56.1 ± 
1.97** 
- 50.4 ± 1.91* 11.7 ± 3.97 
∆H2-
R15∆CT 
242 53.7 ± 1.51 72.9 ± 4.11 49.8 ± 0.54* 36.2 ± 1.95** 
∆R3-
15,18-
23 ∆CT 
146 45.8 ± 2.96 - 47.3 ± 0.07 36.7 ± 3.96** 
hUtr 399 46.2 ± 1.42 - 43.4 ± 0.36 12.5 ± 1.40 
µH2 hUtr 138 47.0 ± 1.16 - 42.9 ± 0.25 25.6 ± 3.58 
 
Table 2.1: Biophysical properties of human dystrophin and utrophin constructs.  
All values are mean values of at least 3 experiments with standard deviations. CD Tm1 
and Tm2: Circular dichroism melting temperatures; DSF Tm: Differential scanning 
flourimetry melting temperatures. * p < 0.05; ** p < 0.0001 using ANOVA statistical 
analysis compared to full-length human dystrophin.  
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Chapter 3 
 
Ubiquitin Proteasome Pathway in   
Novel Mouse Models of Missense Mutant Dystrophins* 
 
 
 
 
 
 
 
 
 
*Manuscript of co-first author paper with Dana M. Talsness to be submitted to Human 
Molecular Genetics in May of 2017.  
 
The initial siRNA screen was performed collaboratively with Dana Talsness and Robert 
Arpke with subsequent validation done by Jackie McCourt. Initial mouse-line 
development and analyses were performed by Dana Talsness collaboratively with Dawn 
Lowe, John Olthoff, Paul Chatterton, and Chris Chamberlain. Development of the 
homozygous mouse line and subsequence analyses was performed by Jackie McCourt 
with physiological analysis done in collaboration with Angus Lindsay.  
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Synopsis 
Missense mutations in the dystrophin protein are thought to cause Duchenne 
(DMD) or Becker (BMD) muscular dystrophy in 0.4% of patients through an undefined 
pathomechanism. In vitro studies suggest that missense mutations in the N-terminal 
actin binding domain (ABD1) cause protein instability and decreased expression levels 
in cultured myoblasts that were restored to wild type by treatment with ubiquitin 
proteasome inhibitors.  To identify the specific ubiquitin-conjugating enzymes 
responsible for targeting dystrophin to the proteasome, we screened a myoblast cell line 
expressing GFP-tagged L54R mutant dystrophin with an siRNA library of E1, E2, and E3 
ligases. The screen identified five putative dystrophin-specific E3 ligases. To further 
elucidate the role of the ubiquitin proteasome pathway in missense dystrophin biology 
and the effects of missense dystrophins in vivo, we generated two missense dystrophin 
mouse lines on the mdx background – L54R and L172H – corresponding to DMD- and 
BMD- associated mutations identified in human patients. The biochemical, histological, 
and physiological parameters measured for these new mouse models demonstrate that 
disease severity is inversely proportional to the amount of missense protein present in 
the muscle. While treatment of the mice with proteasome inhibitors was not effective at 
increasing missense dystrophin protein, increased expression of missense L172H 
dystrophin through the generation of homozygous mice revealed further improvements 
in muscle histology and physiology. Additionally, protein levels for one of the five 
putative dystrophin-specific E3 ligases identified in our screen showed increased levels 
correlating with the amount of missense mutant dystrophin present in each mouse 
model.   This work establishes two novel mouse models representing DMD or BMD 
where the level of dystrophin expression exceeds the accepted therapeutic level for wild 
type protein, and highlights the ubiquitin-proteasome pathway as a mechanism of 
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dystrophin protein regulation relevant for understanding the etiology of DMD/BMD and 
potential therapies.  
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Introduction 
The X-linked recessive disease Duchenne muscular dystrophy (DMD) is 
caused by mutations in the DMD gene encoding for the 427 kDa protein 
dystrophin(Koenig et al., 1988). Dystrophin is predominantly expressed in muscle 
cells and is a critical component of the dystrophin-glycoprotein complex (DGC) 
that functions to stabilize the muscle cell membrane during muscle contraction 
(Ervasti, 2003; Rybakova et al., 2000). Disease-causing mutations in the DMD 
gene vary with 68.5% of patients harboring large deletions (>1 exon), 11% with 
duplications (>1 exon), 10.2% with non-sense mutations, 6% with smaller 
deletions or insertions (<1 exon), 3% with splice-site mutations, 0.3% with mid-
intronic mutations, and 0.4% with missense mutations (Bladen et al., 2015). 
Typically, mutations that result in the absence of dystrophin protein (i.e. through 
nonsense mutations or out-of-frame deletions) cause the severe phenotype of 
Duchenne muscular dystrophy (DMD) whereas mutations that result in a partially 
functional dystrophin cause a milder form known as Becker muscular dystrophy 
(BMD) (Koenig et al., 1989). Exceptions to this categorization include the subset 
of patients with missense mutations that result in only one amino acid change. A 
patient with an L54R mutation in the N-terminal tandem calponin homology (CH) 
actin binding domain (ABD1) was reported as having a severe form of dystrophy 
diagnosed as DMD (Prior et al., 1993) and a patient with a missense mutation in 
a homologous region of ABD1, L172H, was diagnosed with the milder BMD 
(Hamed et al., 2005).  
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 Disease-causing mutations in ABD1 were expected to disrupt actin 
binding activity (Norwood et al., 2000). However, many missense mutations in 
this domain, including L54R and L172H, did not show large differences in actin 
binding affinity but instead demonstrated increased thermodynamic instability 
and aggregation (Henderson et al., 2010; Singh et al., 2010). Additionally, 
myoblast cell culture models expressing L54R or L172H dystrophins revealed 
missense-mutant dystrophin levels that were inversely proportional to in vitro 
stability and disease severity of the corresponding patients (Talsness et al., 
2015). Treatment of these cell lines with proteasome inhibitors or heat shock 
activators resulted in increased missense-mutant dystrophin levels suggesting 
that the mutations cause misfolding and are targeted to the proteasome. 
Because it is not therapeutically practical to treat chronic patients with broad-
spectrum proteasome inhibitors over the course of their lifetime, research has 
more recently focused on inhibitors specific to ubiquitin-conjugating enzymes 
unique for a given disease target (Weathington and Mallampalli, 2014). 
Therefore, we performed an siRNA screen to identify the ubiquitin-conjugating 
enzymes that may specifically target misfolded dystrophins to the proteasome.  
 In addition to understanding the molecular/cellular pathomechanism 
associated with missense-mutant dystrophins, there is also a need to understand 
the consequences of missense mutations within the context of an animal model. 
The first animal model with a missense mutation in dystrophin was reported in a 
line of pigs harboring a point mutation in exon 41 resulting in full-length 
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dystrophin with the amino acid change R1958W (Hollinger et al., 2014). 
Phenotypically, the R1958W pigs appear to most closely model mildly-affected 
BMD patients and express dystrophin at 30% of wild-type levels. While this 
porcine model will likely be a valuable tool in muscular dystrophy research and 
therapy development, there currently is no animal model that harbors a missense 
mutation reported in any patients with Duchenne or Becker muscular dystrophy. 
Here we report the generation of two novel transgenic mouse models expressing 
missense dystrophins reported in human DMD (L54R) and BMD (L172H) 
patients, which we previously modeled in cultured myoblasts (Talsness et al., 
2015).  Analysis of hemizygous L54R and L172H mice on the dystrophin-null 
mdx background, as well as a homozygous L172H line, revealed that disease 
severity inversely correlates with expression levels of dystrophin protein, 
corroborating the results from the cell culture models. These mouse models are 
valuable platforms to continue understanding the mechanism of dystrophin 
protein regulation and to develop new therapies to treat Duchenne and Becker 
muscular dystrophy. 
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Materials and Methods 
siRNA screen in myoblast model 
The L54R mutant dystrophin C2C12 cell line was grown according to (Talsness 
et al., 2015). Cells were seeded to 600,000 and adhered for 4 hours before being 
treated with mouse ON-TARGETplus siRNA library for Ubiquitin Conjugating 
Enzymes Subsets 1, 2, and 3 (Dharmacon). Cells were treated with 40nM siRNA 
pools according to manufacturer’s protocol or treated with 1uM bortezomib as a 
positive control. After 48 hours, cells were trypsinized and resuspended with 50ul 
microliters fluorescence-activated cell sorting (FACS) staining medium: 
phosphate-buffered saline (PBS) (Mediatech, Inc., Manassas, VA) containing 2% 
fetal bovine serum (FBS; HyClone, Logan, UT) supplemented with 1 ug/mL 
Propidium Iodide. FACS analysis was performed on a BD FACSAriaII (BD 
Biosciences, San Diego, CA) and data were analyzed using FlowJo (FlowJo 
LLC, Ashland, OR).  
Cloning and mouse generation 
Full-length mouse dystrophin cDNA (with missense mutations L54R and L172H) 
was subcloned into the Gateway system Entry vector (Life Technologies).  The 
cDNA was then recombined into a vector containing the human skeletal alpha-
actin (HSA) promoter and Vp1 intron that had been adapted to the Gateway 
system.  The expression cassette was cut out of the vector with restriction 
enzymes and sent to the University of Cincinnati Transgenic Mouse Core (L54R) 
or The Scripps Research Institute Mouse Genetics Core (L172H) for pronuclear 
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injection into fertilized eggs.  Injected eggs were transplanted into 
pseudopregnant mice. Progeny were screened for the transgene by genomic 
PCR.  Transgenic mice were crossed onto the mdx background (mL54R and 
mL172H), and transgenic male progeny were analyzed. Homozygous mice were 
generated by breeding transgene positive males with transgene positive females. 
Progeny were then analyzed for homozygosity by genomic quantitative PCR 
using HSA transgene promoter specific primers (see below). All analyses were 
performed on mice 10-14 weeks of age. 
RT-qPCR 
Tissue was pulverized with mortar and pestle in liquid nitrogen.  RNA was 
isolated with the Aurum Total RNA Fatty and Fibrous Tissue (BioRad 732-6870).  
Total RNA was reverse transcribed into cDNA using the iScript™ Advanced 
cDNA Synthesis Kit (Biorad 170-8843).  cDNA was amplified using 
SsoAdvanced™ Universal SYBR® Green Supermix (Biorad 172-5270).  Primers 
for endogenous mouse dystrophin: Forward [TGGCAGATGATTTGGGCAGA] 
and Reverse [CCATGCGGGAATCAGGAGTT].  Primers for transgenic mouse 
dystrophin (for HSA transgene promoter): Forward 
[ACAATGTAGAAGGGTGGGCG] and Reverse 
[GCGTAGAATCGAGACGCGAGG].  Primers for intragenic mouse dystrophin: 
Forward [GCGCCAACACAAAGGACGCC] and Reverse 
[GCTTCAGCCTGGGGCTGCTC].  All measurements were relative to reference 
transcript Hprt: Forward [CCCTGGTTAAGCAGTACAGCCCC] and Reverse 
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[GGCCTGTATCCAACACTTCGAGAGG]. Primers for RT-qPCR of the siRNA 
positive hits are listed in the table below. Measurements were collected with the 
C1000 Touch Thermal Cycler (Biorad) and analyzed with the CFX Manager 
software (Biorad).  
Target Forward Primer Reverse Primer 
ASB5 AAGCTGGGGCTAATGCAAAC CAGGACTCCAGTTGGGCTTT 
VPS41 GCCGAGTATGACCGACCAAA CCCATTCGGCTCAGAAGGTA 
Amn1 GTCAGCTCCTGGAACTATGTCT GTTATCCGACCCCGAATGCT 
FBXO33 TTGGCAATTCATGGTTACACCG GCCCAGTGATACCTGCTCAA 
FBXO16 GCTGCTGAGGTGTTGTCTTTC GATGGTTGAGAGGTGTCCAGG 
Zfand5 GTCACTCAGCCCAGTCCATC GCAGTCAAACCCTGTAAGGC 
SCEL CAATCAACCAAGACGCCAGC TGTGCTTGGAGAGGCATTGT 
NSD1 TCCAGAAGTACCCACCGACT GCGCATCAGACGACCTTTAG 
PHF5A GGTGTGGCTATCGGAAGACT CGGCCCTGGTAAGATCCATAG 
MYLIP TACAGGAGCAGACAAGGCAT TGTATTGGGCGGTGTTCTGG 
Pcgf3 CCAGGAAGCGGAAATGAGGA TGGTTTCACCATTTCGGGGA 
Rnf182 GGCTCTCGATCCTCCCATCG AAGGGCAGCTGAAGGATCTGAC 
TRAF2 GCTACTGCTCCTTCTGCCTG TGGAAAGGCCGAACTACTCTC 
 
Western blot analysis 
Tissue was pulverized with mortar and pestle in liquid nitrogen.  Tissue was then 
lysed with 1% SDS solution with added protease inhibitors [100nM Aprotonin, 
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10mg/ml E-64, 100μM Leupeptin, 1mM PMSF, 1μg/ml Pepstatin] proportional to 
mass of the tissue pellet.  Protein concentration was measured by A280 
absorbance.  Equal concentrations of lysate were then separated by 
electrophoresed at 150V for 1 hour, then transferred to PVDF membrane at 
100V/0.7Amp for 1 hour.  Membranes were blocked in either [5% non-fat milk in 
phosphate buffered saline 0.1% Tween solution] or [5% Bovine Serum Albumin 
in tris buffered saline 0.1% Tween solution] depending on the primary antibody 
for 1 hour. Primary antibodies used were anti-Dys1 (Leica) at 1:100, anti-Dys2 
(Leica) at 1:100, anti-utrophin (Santa Cruz 8A4) at 1:100, anti-α-dystroglycan 
(Millipore 05-593) at 1:1000, anti-β-dystroglycan (vector labs VP-B205) at 1:100, 
anti-dystrobrevin (BD labs 610766) at 1:1000, anti-syntrophin (Abcam 11425) at 
1:1000, anti-pan actin C4 (Seven Hills Bioreagent LMAB-C4) at 1:5000, anti-
Desmin D93F5 (Cell Signaling 5332) at 1:1000, anti-Hsp40 C64B4 (Cell 
Signaling 4871) at 1:1000, anti-Hsp70 (Cell Signaling 4872) at 1:1000, anti-
Hsp90 (abcam 19021) at 1:1000, anti-Phosph-Hsp90α (Cell Signaling 3488) at 
1:1000, anti-Phospho-Hsp27 (Cell Signaling 9709) at 1:1000, anti-Fbxo33 at 
1:500 (Abcam ab90046), and anti-Amn1 at 1:500 (Boster Bio A15649). Blots 
were then incubated in secondary antibodies anti-mouse or anti-rabbit IgG 
Dylight® 800 (Cell Signaling) at 1:10,000 in blocking buffer.  Secondary antibody 
signal was visualized on Licor’s Odyssey® Infrared Imaging System and band 
density calculated with Odyssey Software v2.1.   
Immunofluorescent analysis 
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Quadriceps and gastrocnemius muscles were dissected, frozen in melting 
isopentane, and embedded in optimum cutting temperature (OCT) compound 
submerged in liquid nitrogen.  Transverse sections of 10 µm were cut on a Leica 
CM3050 cryostat, air dried, and then fixed in 4% paraformaldehyde for 10 
minutes.  Sections were washed with PBS (150mM NaCl, 8 mM NaH2PO4, 42 
mM Na2HPO4) before being blocked with 5% goat serum/0.1% Triton X-100 for 
30 minutes.  A secondary block in Rodent Block M (Biocare Medical) was also 
performed for 30 minutes.  The sections were then incubated with primary 
antibodies overnight at 4°C.  Primary antibody dilutions were: NCL-Dys1 (1:20) 
(Leica), NCL-Dys2 (1:20) (Leica), Rb2 (1:20), Utrophin (1:50) (Santa Cruz), α-
Dystroglycan (1:50) (Millipore), β-Dystroglycan (1:50) (Vector Labs), Dystrobrevin 
(BD Biosciences), nNOS (1:50) (Invitrogen), and Laminin (1:1000) (Sigma).  
Sections were then washed with PBS and incubated with Alexa Fluor 488- or 
Alexa Fluor 568-conjugated secondary antibodies (1:500 dilutions) for 30 minutes 
at 37°C.  Sections were washed with PBS and coverslips were applied with a 
drop of Prolong Gold antifade reagent with DAPI (Molecular Probes).  Images 
were collected on a Deltavision PersonalDV microscope equipped with a 
20x/0.75 objective (Applied Precision) and viewed with GIMP (GNU Image 
Manipulation Program) software. 
Histology and CNF count 
Cryosections were cut from the same blocks prepared for immunofluorescence at 
10μm thickness.  Sections were stained with hematoxylin and eosin-phloxine and 
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imaged on Leica DM5500 microscope at 200x total magnification.  A total of at 
least 250 fibers were imaged from each muscle of each mouse and then centrally 
nucleated fibers (CNF) counted as a percentage of the total. 
Serum CK analysis 
Serum samples of the mice were collected by cheek bleed.  The samples were 
diluted 1:20 and then serum creatine kinase (CK) activity analyzed using CK DT 
slides (Ortho-Clinical Diagnostics) and a Kodak Ektachem DT 60 Analyzer.  CK 
activity is reported as U/L. 
Forelimb grip strength 
Mice were gripped at the base of their tail and positioned to grab the DFE series 
digital force gauge (Chatillon) with grip bar attachment. Once the mouse was 
gripping the bar with both hands, the mouse was slowly with consistent force 
pulled perpendicularly away from the grip bar. Five trials were run per mouse and 
the average force was calculated. 
Whole body tension 
Mice were placed between parallel barriers, allowing only for forward movement.  
A slipknot suture was used to attach the base of the mouse tail to a fixed range 
force transducer (BioaPac Systems).  The tail of the mouse was then lightly 
pinched and the subsequent force evoked was measured. Five minute traces 
were collected and the top 5 peaks were averaged for each mouse and then 
normalized to body weight.  Protocol adapted from (Carlson and Makiejus, 1990). 
Activity after exercise 
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Mice were acclimatized to the treadmill for 3 consecutive days, for 5 minutes at 
0m/min followed by 5 minutes at 9m/min at 0° decline.  On the fourth day, 
baseline pre-exercise activity was assessed for 30 minutes using laser-sensor 
activity cages (AccuScan Instruments Inc.).  Mice were then acclimatized to the 
treadmill for 5 minutes at 0m/min at 15° decline.  Without the use of electrical 
shock, mice were then encouraged to walk on the treadmill for 5 min at 5m/min 
followed by 10 minutes at 15m/min.  After exercise, activity was measured for 30 
minutes.  Total number of vertical episodes were counted and post-exercise 
activity reported as a percentage of the pre-exercise activity. 
Eccentric contraction analysis 
Mice were anesthetized with sodium pentobarbitoal and the extensor digitorum 
longus (EDL) muscle dissected out.  Silk suture was used to attach the proximal 
tendon to a static structure and the distal tendon to a force transducer (Model 
300B-LR, Aurora Scientific).  The EDL was suspended in Ringer’s solution 
[120.5mM NaCl, 4.8mM KCl, 1.2mM MgSO4 1.2mM Na2HPO4, 20.4mM NaHCO3, 
10mM glucose, 10mM pyruvate, 1.5mM CaCl2], while 95% O2/5% CO2 was 
bubbled in.  Muscles were lengthened to an optimal tension and this set as the 
optimal length (L0).  Maximal twitch and tetanus were measured.  For 10% length 
change experiments, the EDL muscle was subjected to an eccentric contraction 
protocol consisting of 5 or 10 maximal tetanic stimulations (5.7ms pulses at 
150Hz for 200 ms) while lengthening from 95% to 105% of the L0 at 0.5 lengths 
per second. For 5% length change experiments, the EDL muscle was subjected 
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to an eccentric contraction protocol consisting of 10 maximal tetanic stimulations 
(5.7ms pulses at 150Hz for 200 ms) while lengthening from 97.5% to 102.5% of 
the L0.  Three minutes recovery was allowed between each eccentric contraction 
and maximum force recorded.  Force production was plotted as percentage of 
the first contraction.  
Statistics 
All statistical calculation were performed with JMP® statistics software.  Data are 
presented as mean ± standard error of the mean.  To determine significance for 
all data with three or more groups, one-way ANOVA analysis was performed with 
α=0.05.  Upon significance of the ANOVA, the Tukey post hoc test was 
performed with all pairs of data at α=0.05.  
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Results 
The myoblast cell line expressing GFP-tagged L54R dystrophin was used 
to screen a commercial library of 512 E1, E2, and E3 ligases (Dharmacon/GE 
Life Sciences Ubiquitin Conjugation Subsets 1, 2, and 3) through fluorescence 
activated cell sorting (FACS, Figure 3.1). Sixteen positive hits were identified as 
those with fluorescence values significantly above a background threshold of 
2.5% (Figure 3.2) and were replicated in an identical but separate siRNA 
treatment and FACS analysis. The positive hits of the screen are listed in Table 
3.1. The majority of the hits are either confirmed or putative E3 ligases with only 
three E2 ligases identified in the screen (Ube2e3, DCN1, and Ube2i). Of the 16 
positive hits, 9 were subsequently validated by RT-qPCR to show significant 
transcript knockdown in cells after siRNA treatment (Figure 3.3) and 5 of the E3 
ligases further showed increased GFP-dystrophin fluorescence above the 
background when knocked down in the L172H cell line (Table 3.1).  
 To further characterize the E3 ligases implicated by the screen to target 
missense-mutant dystrophin to the proteasome, we generated transgenic mice 
expressing the L54R or L172H missense mutations in full-length dystrophin 
driven by the human skeletal actin (HSA) promoter and bred them onto the 
dystrophin-deficient mdx mouse line (labeled as mL54R and mL172H mice). 
Tibialis anterior (TA), gastrocnemius, and heart tissues were analyzed by RT-
qPCR and Western blot for dystrophin transcript and protein levels (Figure 3.4). 
The L54R mice had comparable levels of dystrophin transcript compared to wild 
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type mice (Figure 3.4A) but only 7-9% of wild type protein levels (Figure 3.4E). 
Transcript levels in L172H mice were also comparable to wild type (Figure 3.4B) 
but mutant protein levels were only 44% of wild type (Figure 3.4F). L54R and 
L172H protein levels were remarkably similar to the levels measured in the 
corresponding myoblast cell culture model (13% for L54R and 46% for L172H). 
  The mL54R and mL172H mouse lines were analyzed for quantity and 
localization of several components of the dystrophin glycoprotein complex (DGC) 
compared to wild type and mdx mice (Figure 3.5). Both mL54R and mL172H 
lines did not exhibit rescue of DGC component expression by western blot but 
did show proper localization at the membrane. Interestingly, utrophin expression 
in transgenic lines was similar to mdx but nNOS expression was increased and 
was membrane-localized in mL172H mice. Quadriceps muscle sections were 
stained with H&E and assessed for histological signs of dystrophy (Figure 3.6A). 
The mL54R line showed dystrophic features similar to mdx.  The mL172H was 
also dystrophic, but possibly to a lesser degree.  To quantify the histological 
features, the fibers which are centrally-nucleated (CNF) were counted as a 
percentage of total fibers (Figure 3.6B).  The data revealed that mdx had 
significantly more CNFs than wild type, as expected.  The mL54R and mL172H 
lines also had significantly increased CNFs over wild type, but with lower average 
values than mdx.  Indeed mL172H quadriceps had significantly lower CNFs than 
both mdx and mL54R.  Across the four phenotypes, CNF values were inversely 
proportional to the quantity of dystrophin protein measured (Figure 3.4) and 
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consistent with the severity of patient muscular dystrophy symptoms modeled by 
each line.  
 The transgenic mL54R and mL172H lines were assessed for several 
physiological impairments associated with muscular dystrophy in the mdx mouse, 
including grip strength, whole body tension, activity after exercise, and eccentric 
contraction-induced force loss (Figure 3.7) (Petrof et al., 1993; Connolly et al., 
2001; Kobayashi et al., 2008). Wild type mice displayed an average grip strength 
of 32 mN/g (Figure 3.7A), while all three dystrophic lines (mdx, mL54R, mL172H) 
had significantly decreased grip strengths.  Whole body tension, which measures 
the force of both the proximal and distal muscles in all four limbs at once, for wild 
type mice showed approximately 140mN/g of tension (Figure 3.7B).  The mdx 
line gave a large range of variability, but each of the transgenic lines mL54R and 
mL172H were significantly decreased compared to wild type.  The activity levels 
of mice were monitored before and after exercise (Figure 3.7C), and it was found 
that each of the dystrophic lines were significantly less active than wild type.  As 
a final assessment of physiological performance, extensor digitorum longus 
(EDL) muscle was analyzed ex vivo for force loss after eccentric contraction 
(Figure 3.7D).  Wild type mice maintained the same level of force after 5 
eccentric contractions, while mdx, mL54R, and mL172H all dropped to 
approximately 20% of initial force by the 5th eccentric contraction.  A summary of 
all the ex vivo parameters measured (Table 3.2) shows that all three of the 
dystrophic models were significantly different than wild type for specific force, 
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change in specific force after eccentric contractions, and total force drop during 
eccentric contraction.  Together, these data indicate that neither missense 
mutant line was different from mdx suggesting that the L54R and L172H 
dystrophin proteins cannot restore physiologic function.  
 Because we previously showed in the myoblast models of L54R and 
L172H dystrophins that the mutant proteins were being targeted to the 
proteasome (Talsness et al., 2015), we treated the mL54R and mL172H mouse 
models with several different proteasome inhibitors at various concentrations and 
by multiple delivery methods according to protocols previously published (Table 
3.3, Gazzerro et al., 2010; Yang et al., 2011; Stessman et al., 2013; Hurchla et 
al., 2013). None of the treatments showed evidence of an increase in dystrophin 
protein levels by Western blot (Figure 3.8). These results suggest that use of 
proteasome inhibitors is not a viable option for testing whether increasing 
missense dystrophin levels in muscle improved any of the dystrophic parameters 
or confirming whether mutant dystrophin protein was being targeted to the 
proteasome.  
To determine if the missense mutations in dystrophin were stimulating the 
heat shock pathway, the relative abundance of the major heat shock proteins 
was measured by western blot analysis (Figure 3.9).  Quantification from three 
separate sets of animals revealed no difference in the levels of Hsp40, Hsp70, 
Hsp90, or Hsp27P.  Hsp90P levels were almost undetectable.  While there was 
no significant increase, Hsp27P showed an upward trend for the mL54R line, 
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indicating that there may be a slight perturbance to the heat shock pathway. The 
lack of global heat shock response was similar to the missense myoblast model, 
and leaves the heat shock pathway as a possible therapeutic target for 
increasing dystrophin protein levels. 
 Given the ineffectiveness of proteasome inhibitors to elevate mutant 
dystrophin levels in the mL54R and mL172H mouse models (Table 3.3), we 
tested whether mice homozygous for the L172H missense mutant dystrophin 
transgene (mhomL172H) expressed more dytrophin than hemizygous mL172H 
animals and compared the phenotypes of mhomL172H animals with mL172H 
littermates. By Western blot, skeletal muscle from mhomL172H mice expressed 
significantly more dystrophin (~1.5X) than mL172H muscle (Figure 3.10). 
Histologically, mhomL172H mice showed similar fiber size and shape to 
mL172H, but showed a further significant decrease in the number of centrally 
nucleated fibers (Figure 3.11A-B). The mhomL172H animals demonstrated a 
modest but still significant protection from eccentric contraction-induced force 
loss compared to mdx and hemizygous littermates (Figure 3.11C). Protection 
was even more evident when the eccentric contraction protocol was adjusted to a 
5% length change (Figure 3.11D) compared to our standard 10% length change 
protocol (Figure 3.11C). Comparison of ex vivo parameters to other mouse 
models showed significant improvement in specific force of the homozygous 
mice over mL172H mice (Table 3.2). Furthermore, homozygous mice had 
significant improvement in specific force, change in specific force, and force drop 
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compared to mdx, a change that was not seen for mL172H mice. 
 Based on our in vitro studies in myoblasts that missense dystrophins are 
targeted to the proteasome (Talsness et al., 2015), we analyzed muscle tissue 
from each mouse line for changes in expression of the 5 E3 ligases identified 
from the siRNA screen (Table 3.1). Western blots of Rnf182, VPS41, and Zfand5 
using the commercially-available antibodies did not show specific bands of the 
expected molecular weight (data not shown). While the levels of FBXO33 did not 
vary in a pattern consistent with the level of dystrophin expressed, Amn1 
immunoreactivity increased proportional to the amount of missense protein 
expressed (Figure 3.12). These data suggest that Amn1 may be involved in 
regulating the level of missense mutant dystrophins and/or their targeting to the 
proteasome for degradation.  
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Discussion 
Using an siRNA screen in cultured myoblasts, we have identified five E3 
ligases that may be involved in targeting missense dystrophins to the 
proteasome. Rnf182, or ring-finger like protein 182, has been shown to have E3 
ubiquitin ligase activity in vitro, interacts with a complex that functions in gap 
junctions and neurotransmitter release channels, and has altered expression in 
Alzheimer’s disease (Liu et al., 2008). Zfand5, also known as Znf216, is a zinc-
finger and AN1-like domain containing protein that has been shown to interact 
with IKKgamma (Huang et al., 2004) and, more notably, has been implicated in 
muscle atrophy (Hishiya et al., 2006). VPS41 is a part of the regulated secretory 
pathway and endocytic pathways in mammalian cells(Wada, 2013) but contains 
a RING-H2 domain present in a number of ubiquitin ligases(McVey Ward et al., 
2001). FBXO33 is a component of the SCF (Skp1/Cul1/F-box) E3 ubiquitin ligase 
(Lutz et al., 2006), was identified as a seizure response gene (Flood et al., 2004) 
and as a target of the DUX4 transcription factor that is activated in 
facioscapulohumeral muscular dystrophy (Geng et al., 2012). Amn1 has been 
implicated in cell cycle regulation and a putative interactor with the E3 ligase 
APC (anaphase-promoting complex) (Wang et al., 2003). With the exception of 
FBXO33, the E3 ligases we identified have not been previously associated with 
muscular dystrophy and none of them have been reported to bind to or 
ubiquitinate dystrophin. 
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We have also generated two novel transgenic mouse lines, representing 
severe DMD (L54R) and mild BMD (L172H) caused by missense mutations in 
dystrophin.  The original reports of missense mutations L54R and L172H were 
more than a decade apart from each other and therefore could not be compared 
side by side (Prior et al., 1993; Hamed et al., 2005). While the physiology of the 
patients was well reported, the molecular analysis was minimal, with both groups 
estimating that the patient expressed 20% dystrophin levels. Here we measured 
steady state dystrophin levels  of 7-9% for L54R and 44% for L172H. These 
results correlate with the level of protein seen in the cell culture models and 
dystrophin expression can be ascribed to the degree of in vitro misfolding as 
seen by differential scanning fluorimetry (Talsness et al., 2015). The mL54R line 
presented with biochemical, histological, and physiological phenotypes 
synonymous with the mdx mouse, whereas the mL172H line was more 
consistent with an improved, BMD-like phenotype. Therefore dystrophin protein 
abundance inversely correlates with disease severity in mice and we believe this 
is the major mechanism of disease.  
Previous studies on the relationship between dystrophin protein 
expression and disease phenotype have also shown that disease severity 
inversely correlates with dystrophin protein levels (Wells et al., 1995; Phelps et 
al., 1995). Transgenic mice expressing only 20% of full-length or a therapeutic 
mini-dystrophin demonstrated rescue of dystrophic phenotype. Our mL172H 
mouse line expressing 40% dystrophin levels should thus theoretically be able to 
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ameliorate the dystrophic phenotype but instead only shows partial improvement 
in some parameters, suggesting that the L172H mutation disrupts dystrophin 
function in addition to protein stability. Other studies of dystrophin levels using 
non-transgenic mouse models with varying levels of dystrophin demonstrated 
that as little as 5% of wild-type dystrophin is sufficient to partially protect from 
some of the dystrophic phenotypes (Li et al., 2008; van Putten et al., 2012), 
suggesting that the L54R mutant expressed at 7-9% with no protection also has 
disrupted functionality.  
To address the question of quality (functionality) versus quantity 
(dystrophin levels), we sought to increase dystrophin protein levels by treating 
mice with various proteasome inhibitors and heat shock activators as seen in the 
myoblast cell culture models. In all cases, there was no evidence of increased 
dystrophin protein upon treatment. One study on the use of proteasome inhibitors 
in mdx mice showed an improvement in muscle phenotype and an increase in 
DGC complex members at the plasma membrane (Bonuccelli et al., 2003) but we 
did not see a similar response. It is possible that the drugs are not at sufficient 
levels to inhibit the proteasome in muscle to produce the intended effect of 
increased dystrophin protein, leading us to generate homozygous transgenic 
mice to genetically increase missense dystrophin levels. We hypothesized that a 
homozygous L54R mouse would not produce high enough dystrophin levels to 
see an improvement, thus we focused our efforts on generating and 
characterizing the L172H homozygous line. The homozygous mice showed >1.5 
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fold increase in dystrophin levels compared to hemizygous littermates, 
demonstrating that L172H mutant dystrophin levels are able to be manipulated. 
The homozygous L172H line showed significant improvements in central 
nucleation, specific force, and eccentric contraction-induced force drop compared 
to hemizygous mice, indicating that higher levels of missense dystrophin are able 
to partially compensate for impaired functionality.  
Finally, we were able to detect FBXO33 and Amn1 proteins in muscle 
tissue of wild-type, mdx, and missense dystrophin transgenic lines and observed 
that Amn1 levels increase as levels of missense dystrophin increase, with the 
highest level of expression in the homozygous L172H line. These data support 
our hypothesis that missense dystrophin proteins are being regulated by the 
ubiquitin-proteasome pathway. In future studies, we aim to knockdown Amn1 
levels in our mice and evaluate the effect on missense dystrophin expression. 
In summary, this work establishes two novel mouse models of missense 
dystrophins and, in particular for the L172H line, establishes the first animal 
model of BMD incorporating a mutation found in a patient. The proposed primary 
mechanism of disease in these models is through degradation of misfolded 
missense dystrophin proteins via the ubiquitin-proteasome pathway. The 
implications of this work are not limited to missense mutants only but can also 
apply to other potentially misfolded dystrophin proteins, such as internally deleted 
dystrophins (Henderson et al., 2011; McCourt et al., 2015) found in BMD 
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patients, those miniaturized dystrophins under investigation as therapeutic 
constructs for gene therapy, or  in exon skipping therapies.  
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Figures 
 
 
Figure 3.1: Experimental design for siRNA screen. The transgenic C2C12 cell line 
expressing GFP-L54R dystrophin was used to screen a library of 512 siRNAs targeting 
E1, E2, and E3 ligases. Fluorescence activated cell sorting (FACS) was used to screen 
for increased GFP fluorescence indicating an increase in L54R dystrophin protein levels.  
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Figure 3.2: FACS plots of positive hits from siRNA screen. FACS plots generated 
from FlowJo of untreated cells, 1µM bortezomib (Bz) treated cells, a representative 
negative hit of below the 2.5% GFP threshold (CUL5), and the 16 positive hits above the 
threshold in order of increasing GFP fluorescence.  
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Figure 3.3: Validation of specific siRNA knockdown of 16 positive hits. RT-qPCR 
analysis of siRNA treated cells for each of the 16 positive hits compared to untreated 
cells. ANOVA F<0.05, * p<0.05 to untreated control. 
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Figure 3.4: RNA and protein expression levels in transgenic mouse lines.  (A) and 
(B) RT-qPCR analysis for mouse lines L54R and L172H respectively.  Top panel shows 
amplification within the 3’UTR of endogenous mouse dystrophin. Middle panel shows 
amplification within the 3’UTR of the transgenic dystrophin. Bottom panel shows 
amplification within the coding region of dystrophin, amplifying both endogenous and 
transgenic dystrophin.  n=3 separate animals for each line.  ANOVA analysis of the 
intragene amplifications were F<0.05 for both L54R and L172H lines. Post hoc analysis 
between wild type and transgenic were n.s. (not significant).  (C) and (D) Representative 
western blot analyses of mouse lines L54R and L172H respectively.  (E) and (F) 
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Quantification of western blots from n=3 separate animals for each line.  ANOVA 
analysis for both lines gave F<0.05.  Post hoc analysis ✱p<0.05 compared to wild type.   
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Figure 3.5: Expression levels and localization of components in the Dystrophin 
Glycoprotein Complex.  (A-C) Utr = utrophin, α-DG = alpha-dystroglycan, β-DG = beta-
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dystroglycan, DB = dystrobrevin, Syn = syntrophin, nNOS = neuronal nitric oxide 
synthase.  (A) Representative western blot analyses for several components of the DGC 
in tibialis anterior muscle, including two different antibodies for dystrophin corroborating 
results found in Figure 4.2.  (B) Quantification of western blots for n=3 separate animals 
for each line.  Values are all normalized to wild type for each blot. ANOVA with 
significance of F<0.05 were analyzed with post hoc statistics.  ✱p<0.05 compared to wild 
type.  #p<0.05 between mdx and L172H.  (C) Immunofluorescent analysis of 
components of the DGC in quadriceps muscle. Scale bar = 20μm. 
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Figure 3.6: Fiber morphology and permeability. (A) Representative quadriceps 
muscle sections stained with H&E and imaged at 20x magnification.  Scale bar = 20μm.  
(B) Quantification of centrally nucleated fibers (CNF) as a percentage of the total fibers.  
A minimum of 250 fibers were counted for each mouse.  n=5 for b6 and mdx, n=6 for 
mL54R and mL172H.  ANOVA analysis was significant at F<0.0001. Post hoc analysis 
gave ✱p<0.001 for wild type versus all disease models, and for mL172H versus mdx and 
mL54R.  (C) Serum creatine kinase (CK) activity from cheek bleeds of individual mice.  
n=5 for b6, n=9 for mdx, n=7 for mL54R, n=9 for mL172H. ANOVA analysis was 
significant at F<0.01.  Post-hoc analysis gave ✱p<0.01 for wild type versus mdx.  Both 
transgenic lines were not statistically different from wild type.   
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Figure 3.7: Physiology of transgenic mouse models. (A-C) n=6 for b6, n=9 for mdx, 
n=7 for mL54R, n=5 for mL172H. (A) Forelimb grip strength analysis.  Individual points 
are an average of 5 trials for each mouse. ANOVA was significant at F<0.001.  Post hoc 
analysis gave ✱p<0.005 compared to wild type.  (B) Whole body tension analysis.  
Individual points are an average of 5 trials for each mouse.  ANOVA was significant at 
F<0.01.  Post hoc analysis gave ✱p<0.05 compared to wild type.  (C) Activity after 
exercise analysis.  ANOVA was significant at F<0.005.  Post hoc analysis gave ✱p<0.05 
compared to wild type.  (D) Ex vivo EDL force measurement during eccentric 
contraction. n=4 for b6, n=5 for mdx, n=6 for mL54R, n=5 for mL172H. Data for b6 mice 
taken from Belanto et al. (PNAS 2014).  For ECC 2-5, all three dystrophic models were 
significantly different than wild type.   
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Figure 3.8: Dystrophin western blot analysis of drug-treated mice. Dystrophin 
western blot analysis of quad muscle lysates from mice treated with sham (solvent only) 
or various proteasome inhibitors (bortezomib – Bz, oprozomib – oproz, carfilzomib – 
carf, and MG132) or a heat shock activator (gedunin – ged) compared to an untreated 
b6 wild type mouse. Dosages, solvents, and delivery methods are outlined in Table 3.3.  
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Figure 3.9: Effect of missense mutations on the heat shock pathway of the mice.  
(A) Representative western blots of heat shock proteins in each of the mouse lines from 
tibialis anterior muscle.  Hsp90P was barely detectable.  (B) Quantification of n=3 sets of 
mice.  ANOVA analysis for each protein was not significant. 
  82 
 
Figure 3.10: Protein expression levels in transgenic homozygous L172H mice. (A) 
western blot of wild-type (B10, n=3), hemizygous littermates (mL172H, n=4), and 
homozygous mice (mhomL172H, n=4) with GAPDH loading control (B) Quantification of 
western blots. Unpaired t-test, * p<0.05. 
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Figure 3.11: Histological and physiological analysis of transgenic homozygous 
L172H mice. (A) Representative quadriceps muscle sections from homozygous mice 
(mhomL172H) and hemizygous mice (mL172H) stained with H&E and imaged at 20x 
magnification. Scale bar = 20µm. (B) Quantification of centrally nucleated fibers (CNF) 
as a percentage of the total fibers. A minimum of 250 fibers were counted for each 
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mouse (n=3). Unpaired t-test, ✱p<0.05. (C-D) Ex vivo EDL force measurement during 
eccentric contraction at 10% lengthening (C) or 5% lengthening (D). B10 n=3, mdx n=3, 
mhemL172H n=6 (10%) or n=3 (5%), mhomL172H n=10 (10%) or n=4 (5%); ANOVA, 
post hoc analysis gave ✱p<0.05 compared to mdx.   
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Figure 3.12: FBXO33 and Amn1 protein expression levels in transgenic mouse 
models. (A) Western blot of wild-type (B10, n=3), mL54R (n=3), hemizygous littermates 
(mL172H, n=3) and homozygous L172H (mhomL172H, n=3). (B) Quantification of 
western blots. One-way ANOVA, * p<0.05, ** p<0.01, *** p<0.001 
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Table 3.1: Summary of positive hits from siRNA screen. Table of the 16 positive hits 
(above 2.5% GFP threshold in L54R cell line) with gene accession numbers, significant 
(*) or not significant (ns) knockdown by RT-qPCR, and %GFP in L172H cell line. Hits in 
red are those with both significant knockdown by RT-qPCR and above a 0.06% 
threshold in L172H cell line.  
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Table 3.2: Summary of ex vivo EDL parameters. For measurements of specific force, 
change in specific force, and force drop during eccentric contractions ANOVA was 
significant at F<0.01. Post hoc analysis gave # p<0.05 compared to wild type, † p<0.05 
compared to mdx, ǂ p<0.05 compared to mL172H. 
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Table 3.3: Protocols for drug treatment of mice from Figure 3.8. Specific dosages, 
solvents, and delivery routes for each panel of Figure 3.8.  
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Synopsis 
 Patients with Duchenne muscular dystrophy (DMD) lack the protein dystrophin 
(Koenig et al., 1989), which is a critical molecular component of the dystrophin-
glycoprotein complex (DGC). Dystrophin is hypothesized to function as a molecular 
shock absorber or spring that mechanically stabilizes the sarcolemma of striated muscle 
through interaction with the cortical actin cytoskeleton via its N-terminal half with the 
transmembrane protein α-dystroglycan via its C-terminus (Rybakova and Ervasti, 1997; 
Ervasti, 2007).  Utrophin is a fetal homologue of dystrophin that can subserve many 
dystrophin functions (Matsumura et al., 1992; Rybakova et al., 2002b) and is therefore 
under active investigation as a dystrophin replacement therapy for DMD (Guiraud et al., 
2015). Here, we report the first mechanical characterization of utrophin using atomic 
force microscopy (AFM). Our data indicate that the mechanical properties of spectrin-like 
repeats of utrophin are more in line with the Ig-like repeats of titin rather than those 
reported for repeats in spectrin or dystrophin.  Despite exhibiting identical thermal 
denaturation profiles (Henderson et al., 2011), we also measured markedly different 
mechanical characteristics for the spectrin repeats within the N-terminal actin-binding 
half of utrophin compared to those in the C-terminal dystroglycan-binding half. Spectrin 
repeats in the N-terminal half displayed a “brittle” behavior where the unfolding forces of 
individual repeats were remarkably uniform upon extension. In contrast, spectrin repeats 
in the C-terminal half exhibited characteristics of a stiffening spring with unfolding forces 
increasing dramatically with extension. AFM measurements of full-length utrophin 
demonstrate mechanical properties most consistent with the C-terminal half showing 
increasing resistive force upon extension but with much larger forces. Our results 
demonstrate dramatic differences in the mechanical properties of two structurally 
homologous utrophin constructs both dominated by repetitive spectrin-like motifs and 
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suggest that utrophin may function as a stiff elastic element in series with titin at the 
myotendinous junction.  
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Introduction 
 Duchenne muscular dystrophy (DMD) is a fatal muscle disease afflicting one in 
every 4000 boys (Mendell et al., 2012) and is caused by mutations in the DMD gene 
encoding the 427 kDa cytoplasmic protein dystrophin (Hoffman et al., 1987). Dystrophin 
is predominantly expressed in striated muscle and through interaction with the 
dystrophin-glycoprotein complex (DGC) at the muscle cell membrane, or sarcolemma 
(Ervasti, 2003). Disease-causing mutations in the DMD gene lead to an absence or loss 
of function of dystrophin, resulting in loss of sarcolemmal integrity and muscle fiber 
death (Rybakova et al., 2000).   
 Dystrophin is composed of three major functional domains: the N-terminal calponin 
homology actin binding domain (ABD1), a large central rod domain containing triple 
helical spectrin-like repeats, and the cysteine-rich C-terminal (CRCT) domain that binds 
the transmembrane dystroglycan complex and other proteins. It has long been 
hypothesized that dystrophin acts as a molecular spring or shock absorber to 
mechanically stabilize the sarcolemma during muscle contraction (Ervasti, 2007). 
Because the homologous protein utrophin can compensate for dystrophin deficiency in 
the mdx mouse model (Tinsley et al., 1998), pharmacologic upregulation of utrophin is 
under investigation as a therapeutic approach for DMD (Guiraud et al., 2015). While 
many of the biochemical and biophysical properties of dystrophin and utrophin have 
been characterized, only two studies have mechanically characterized dystrophin 
(Bhasin et al., 2005; Krieger et al., 2010) and no studies have investigated the 
mechanical properties of utrophin. Here, we report atomic force microscopy analysis of 
single protein molecules representing the N-terminal actin-binding half (Utr NT-R10), the 
C-terminal dystroglycan-binding half (Utr R11-CT), and full-length utrophin (Figure 4.1A).  
  93 
Methods 
Cloning 
Full-length mouse utrophin was previously cloned from an existing vector into a 
pENTR/D-TOPO vector (Invitrogen™) with an 8-amino acid FLAG-tag (DYKDDDDK) 
added to the N-terminus of utrophin for use in purification(Guo et al., 1996; Rybakova et 
al., 2002a). All utrophin truncation constructs were PCR amplified using primers 
designed around adjacent repeats for the desired deletion based on reported repeat and 
domain boundaries(Winder et al., 1995). The PCR products were circularized using T4 
polynucleotide kinase and T4 DNA ligase (New England BioLabs) and sequence 
verified. Using the Gateway Recombination system (Life Technologies), the deletion 
constructs were recombined into the pDEST8 destination vector and subsequently 
transformed into DH10Bac competent E. coli and purified according to the 
manufacturer’s protocol.   
Protein expression and purification 
Sf9 insect cells were maintained at 1 x 106 cells/mL in Sf-900™ II SFM (Life 
Technologies). Purified Baculovirus was transfected using Cellfectin® II (Life 
Technologies) and high-titer viral stocks were generated through successive infections 
of Sf9 cells in 3.5 cm plates (P0), 10 cm plates (P1), and 250 mL of 1 x 106 cells/mL 
suspended cells (P2). Ten mL of P2 virus were used to infect 250 mL of 1 x 106 cells/mL 
and cultured for 72-hour post-infection to maximize protein expression. Infected cells 
were centrifuged at 1,000 x g for 3 minutes and re-suspended in lysis buffer containing 
phosphate buffered saline (PBS), 1% Triton, and a cocktail of protease inhibitors [100nM 
Aprotinin, 10mg/mL E-64, 10μM Leupeptin, 1mM PMSF, 1μg/mL Pepstatin]. The lysate 
was centrifuged at 14,000 x g for 10 min at 4ºC and the supernatant applied to an anti-
FLAG M2 agarose column (Sigma Aldrich). The column was washed with >10 column 
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volumes of PBS and bound protein eluted with PBS containing protease inhibitors and 
100µg/mL FLAG peptide. After dialysis overnight in 2L of PBS at pH 7.5, the purified 
protein was concentrated using the Amicon Centrifugal Filter unit (UFC801024) and 
protein concentration was determined using A280 and extinction coefficients calculated 
from the amino acid compositions for each construct. Concentrated proteins were run on 
a 3-12% SDS polyacrylamide gradient gel and run at 150V for 1 hour. Gels were stained 
with Coomassie blue stain and visualized using Licor’s Odyssey® Infrared Imaging 
System. 
Circular Dichroism 
Each purified protein was centrifuged at 14,000 x g for 10 minutes at 4ºC and the 
supernatant diluted to 0.4 mg/mL using PBS. Absorption spectra were acquired with a 
Jasco J-815 spectropolarimeter, initially at 20°C as controlled by a Peltier device, from 
200 to 260nm wavelength. Spectra were then acquired at 1°C temperature intervals from 
20-90°C and the characteristic ellipticity at alpha-helical wavelength (θ222) recorded. 
Molar ellipticity, [θ], was calculated using the following equation: [θ] = θ / (10 x c x l) 
where c is the molar concentration of the sample (mole/L) and l is the path-length in cm. 
Molar ellipticity (with units of degrees, cm squared per decimole) was plotted against 
wavelength for the circular dichroism (CD) spectra. Ellipticity at 222nm (θ222) was 
normalized, plotted against temperature, and fit by regression analysis in Sigma Plot 
(Systat Software, Inc.) using equations for two state unfolding (Legardinier et al., 2009).  
Atomic Force Microscopy 
The single molecule force spectroscopy experiments were performed utilizing a MFP-3D 
atomic force microscope (AFM) from Oxford Instruments.  The AFM setup contains a 
flexible cantilever with a sharp tip, a laser-photodiode based sensor which measures the 
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position of the cantilever tip, and a piezo electric nano-positioner which can move a 
substrate in three spatial directions with respect to the cantilever base (Binnig et al., 
1986). We used a soft BioLever (BL-RC-150VB) from Asylum Research with a typical 
spring constant of 6 pN/nm and a 25±12 nm tip radius coated with Cr/Au. A droplet 
(~100 µl) of the protein solution is employed on freshly cleaved mica substrate and 
allowed to settle for 10 minutes before commencing the experiment to ensure that some 
proteins get adsorbed on the mica surface. The cantilever tip is brought towards the 
mica surface, pressed against the surface for 3 seconds with a force ranging from 1000-
2000 pN and then retracted with a specified retraction velocity. The approach-retraction 
cycle is repeated. During such a cycle, if a part of a protein molecule gets attached to 
the cantilever tip with another part adsorbed on the substrate, the interior is stretched 
during the retraction phase of the cantilever. The pulling force on the molecule is 
balanced by the force on the cantilever which can be measured by observing the 
deflection of the cantilever tip when the cantilever spring constant is known. The exact 
spring constant is measured before the pulling experiments by analyzing the thermal 
response of cantilever deflection. Forced extension causes the folded domains in the 
molecule to unfold, which can be detected by a characteristic saw-tooth pattern 
observed in the cantilever deflection (Rief et al., 1999) vs separation curve. Data from 
300-500 successful force spectroscopy experiments are collected for each protein 
construct which reveal the statistical behavior of the unfolding forces of these molecules.  
Data Analysis 
Data from each of the successful protein pulling experiments are collected and analyzed 
using the Igor Pro software from Oxford Instruments. Collected data include the 
separation of the cantilever base from the substrate surface from which the extension of 
the molecule is calculated. The data also include the measured deflection of the 
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cantilever tip as a function of separation. Since the cantilever deflection is proportional to 
the force applied on it, the measured deflection can be converted to the force acting on 
the cantilever by multiplying by the spring constant of the cantilever. The extension of 
protein molecules in between successive unfolding events is fit with the worm like chain 
(WLC) models in Igor Pro software.  The WLC model (Rief et al., 1999), which relates 
the force (F) exerted on the molecule to its extension ( ) is shown in Equation 1.  
 
 
(1) 
The parameters of the model are the persistence length (P) and the contour length (L), 
whose statistics have been obtained for each utrophin construct. T is the temperature 
and  the Boltzmann constant. As a validation of our experimental setup and data 
analysis procedure, we also extracted the statistics of the persistent length and contour 
length for the reference protein titin I27O which matched well with the data reported in 
existing literature (Carrion-Vazquez et al., 1999). 
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Results 
 Previous atomic force microscopy studies have defined the mechanical properties 
of titin as a “stiff’ spring (Rief et al., 1997; Carrion-Vazquez et al., 1999) and spectrin as 
a “soft” spring (Rief et al., 1999; Law et al., 2003b; a). In such experiments, the 
mechanical extensibility of single protein molecules is measured and the unfolding 
forces of individual domains upon extension are collected over a large number of 
experiments to obtain statistical properties of unfolding behaviors. We first obtained AFM 
data for a recombinant titin reference protein (Figure 4.2) and spectrin (Figure 4.3) that 
agree well with previously published values (Carrion-Vazquez et al., 1999; Rief et al., 
1999). AFM data for Utr NT-R10, Utr R11-CT and utrophin all showed characteristic 
saw-tooth patterns of individual domain unfolding (Figure 4.1B-D). From the force versus 
extension curves, we initially observed that the range of unfolding forces for utrophin 
proteins was significantly larger than the unfolding forces reported for spectrin and even 
in fragments of dystrophin (100 – 2000 pN in Figure 4.1B-D versus <50 pN; Bhasin et 
al., 2005; Krieger et al., 2010). More interestingly, Utr NT-R10 showed uniform unfolding 
forces upon extension whereas Utr R11-CT and full-length utrophin showed increasing 
unfolding forces with extension.  
 To determine if these initial observations were consistent statistically, we collected 
data for 300 – 500 successful pulling experiments for each protein construct and 
analyzed the force distribution and contour length, and persistence length (Figure 4.4 
and 4.5). The overall unfolding force distributions between the utrophin constructs do not 
show significant differences (Figure 4.4A-C). However, analysis of the force distribution 
as a function of the unfolding event count within individual force traces revealed unique 
behaviors for Utr NT-R10 and Utr R11-CT (Figure 4.6). For Utr NT-R10, the force 
distributions for increasing unfolding events overlapped with each other (Figure 4.6A), 
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demonstrating a “brittle” behavior. The force distributions for Utr R11-CT (Figure 4.6B) 
and full-length utrophin (Figure 4.6C) were right-shifted and broadened as the unfolding 
event increased, demonstrating a stiffening spring behavior. The mechanical differences 
demonstrated between Utr NT-R10 and Utr R11-CT are in striking contrast to previously 
published circular dichroism data showing nearly identical thermal melt profiles for these 
same proteins (Henderson et al., 2011). 
 One explanation for the different mechanical properties of Utr NT-R10 and Utr 
R11-CT is that their 10-12 homologous spectrin-like repeats are controlled by long-range 
intra-protein communication from the unique ABD1 and/or CRCT terminating domains. 
Thus, we expressed and purified (Figure 4.7A-B) three new utrophin constructs deleted 
for ABD1 (Utr R1-10), CRCT (Utr R11-22) or both ABD1 and CRCT (Utr R1-22). Circular 
dichroism spectroscopy revealed highly similar thermal melt profiles for all three 
constructs (Figure 4.7C). Despite the absence of terminal ABD1 and/or CRCT domains, 
all three utrophin constructs maintained the brittle, or stiffening behaviors (Figure 4.7D-
F) observed with the original domain-terminated constructs (Figure 4.6A-C).  
 Finally, we plotted the average peak forces as a function of unfolding events 
obtained from 300-500 successful pulling experiments (Figure 4.8 and Figure 4.9). 
Figure 4.9 visually demonstrates the striking differences between the N-terminal half (red 
and green plots) and C-terminal half (blue and cyan plots) of utrophin independent of 
their unique terminating domains (ABD1 and CRCT, respectively). Our results suggest 
the sequences of homologous spectrin-like repeats within the N-terminal and C-terminal 
halves of utrophin encode information that dramatically influences their respective 
mechanical behaviors. Additionally, Figure 4.9 reveals that full-length utrophin both with 
and without its terminating domains (pink and black plots) exhibits mechanical behavior 
directed by the C-terminal half.  
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Discussion 
 In comparison to single molecule force spectroscopy data for other spectrin-like 
repeat containing proteins (Bhasin et al., 2005; Krieger et al., 2010), our results for 
utrophin reveal much higher forces of unfolding and stiffening behavior more similar to 
the mechanically stiff spring titin (Zhu et al., 2009; Kellermayer et al., 2003). The 
consistently linear increase in the contour length with increasing unfolding events (Figure 
4.10) as well as contour length peak values that are consistent with single repeats 
(Figure 4.5) argues against the possibility that the high unfolding forces observed for 
utrophin are due to simultaneous unfolding of multiple repeats. It is more likely that the 
differences in measured forces of unfolding of spectrin repeat-containing proteins are 
influenced by sequence differences. Of the spectrin family of proteins, dystrophin and 
utrophin exhibit lower sequence similarity in comparison to the other family members 
(alpha-actinin, alpha-spectrin, and beta-spectrin) (Nicolas et al., 2014). Dystrophin and 
utrophin also have much weaker conservation between repeat units, with a lower 
number of conserved residues and greater number of insertions compared to repeats 
within the spectrins (Winder et al., 1995). Our data are the first to demonstrate markedly 
different mechanical behaviors for structurally homologous spectrin-like repeats within 
the same molecule. 
 In vivo mechanical studies of plasma membrane adhesion complexes such as 
integrins and cadherins have revealed unfolding forces that were more within the ~25 pN 
range of those measured for repeats in spectrin, or dystrophin measured in vitro (Chang 
et al., 2016; Buckley et al., 2014; Bhasin et al., 2005). The surprisingly high unfolding 
forces of utrophin measured here, particularly in Utr R11-CT and full-length utrophin, 
suggest that utrophin is too stiff to also function as a spring that protects the sarcolemma 
from mechanical stress.  Alternatively, the stiffness of utrophin is more consistent with its 
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localization to the myotendinous junction (MTJ) (Ohlendieck et al., 1991), the primary 
site of muscle force transmission to bone where perhaps utrophin may function in series 
with titin as a restorative elastic element (Charvet et al., 2012).  
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Figures 
 
Figure 4.1: AFM extension characteristics of utrophin terminal constructs. (A) 
Schematic of constructs analyzed by AFM. (B) Force vs extension representative trace 
curve for the N-terminal half of utrophin, Utr NT-R10, shows uniform unfolding forces 
upon extension. (C) Force vs extension representative trace curve for the C-terminal half 
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of utrophin, Utr R11-CT, shows increasing unfolding forces upon extension. (D) Force vs 
extension representative trace curve for full-length utrophin, Utr FL, also shows 
progressive increases in unfolding forces upon extension.  
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Figure 4.2: Statistics of Titin I27OTM from AthenaES® (an AFM Reference Protein 
with 8 repeats of the Ig 27 domain of human titin) (A) Histogram of unfolding forces 
with the mode at 220 pN when pulled at 1um/s with a cantilever of spring constant 6.67 
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pN/nm. This matches closely with the reported value of 224 pN (Carrion-Vazguez et al., 
1999).  (B) The histogram of contour length increments indicates that the most probable 
value is 27.5 nm, while 28.4 nm was the corresponding reported value (Carrion-Vazguez 
et al., 1999). (C) The peak persistence length was measured to be 309 pm compared to 
the reported value of 390±70 pm (Carrion-Vazguez et al., 1999). (D) Box plots of the 
unfolding forces classified based on the unfolding count, with the red line indicating the 
median value and the dotted black line indicating the mode. The edges of the box 
represent the 25% and 75% percentiles, with the whisker plots marking the minimum 
and maximum recorded values excluding the outliers.  Titin behaves like a stiff but 
‘brittle’ spring, with the unfolding forces (mode) ranging from 200 pN to 250 pN (a 25% 
increase) for unfolding counts of 1 to 8 respectively. 
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Figure 4.3: Statistics of Spectrin extracted from human erythrocytes from SIGMA-
ALDRICH®. (A) Unfolding force histogram shows that a mode of 26.3 pN for spectrin, 
when pulled at 0.25 um/s with a cantilever of spring constant 6.88 pN/nm.  A value of 28 
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pN was reported in literature under similar conditions (Rief et al., 1999). (B) The most 
probable contour length increment was found to be 25.8 nm, consistent with a value of 
31.7 nm from the earlier report (Rief et al., 1999). (C) The persistence length mode was 
measured at 79.3 pm. (D) The unfolding forces vary from 26 pN for the first unfolding 
event to 40 pN for the sixth (a 54% increase), indicating that the molecule exhibits a 
mildly stiffening spring behavior. 
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Figure 4.4: Unfolding Force histograms for Utr NT-R10, Utr R11-CT, and full-length 
utrophin. The unfolding forces are reported for a pulling speed of 1 um/s with cantilever 
spring constants between 5.04-9.06 pN/nm. 
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Figure 4.5: Contour Length Increment histograms for Utr NT-R10, Utr R11-CT, and 
full-length utrophin. The most probable contour length increments range between 35.2 
to 63.1 nm. 
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Figure 4.6: Unfolding force distributions for utrophin terminal constructs reveal 
markedly different mechanical behaviors. (A) The plot of the probability distribution of 
unfolding force (p(f)) vs the unfolding force for Utr NT-R10 is shown. Here, ‘N’ in the 
legend represents the unfolding event count. For example, the distribution corresponding 
to N = 4 represents the distribution of the 4th unfolding event. For Utr NT-R10, the 
distributions have significant overlap, indicating that the unfolding forces remain uniform 
across unfolding events (referred in this paper as ‘brittle’). (B) The distributions for Utr 
R11-CT differ both in their peak locations and widths across the different unfolding 
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events. We observe that the peak of the distributions shifts right with increasing 
unfolding events, resulting in a stiffening spring behavior. (C) The full length utrophin 
largely shows behavior similar to Utr R11-CT, a stiffening spring, with increasing 
distribution widths and a shift of the peak towards the right with increasing unfolding 
events.   
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Figure 4.7: Unique mechanical behavior of utrophin halves is maintained upon 
deletion of the terminal domains. (A) Schematic of constructs lacking terminal 
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domains. (B) Coomassie-stained gel of 5ug aliquots of purified utrophin proteins. (C) 
Circular dichroism melt curves of terminally-deleted utrophin constructs exhibit similar 
thermal melting compared to full-length utrophin. (D) Probability distributions vs 
unfolding forces for the actin binding half of utrophin without the N-terminus (Utr R1-10) 
maintains a brittle behavior compared to Utr NT-R10 (Figure 4.6A). The distributions for 
the different unfolding events overlap, with closely located peaks. (E) The dystroglycan-
binding half with the C-terminus removed (Utr R11-22) does not produce a substantial 
difference in its stiffening spring characteristic compared to Utr R11-CT (Figure 4.6B). 
(F) Similar to its halves, utrophin without the N and C termini (Utr R1-22) does not exhibit 
a change in behavior compared to full length utrophin (Figure 4.6C), and maintains a 
stiffening spring behavior.  
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Figure 4.8: Box plots of unfolding forces as a function of unfolding count. 
Unfolding events are represented as ‘Ni’, i = {1,2,3…} and ‘d’ denotes the number of 
pulling experiments that resulted in ‘Ni’ events. Utr NT-R10 and Utr R1-R10 can be seen 
to exhibit ‘brittle’ behavior, wherein the unfolding force for the 10th unfolding event is 
comparable to that of the 1st unfolding event. The dystroglycan-binding halves of 
utrophin (Utr R11-CT and UTR R11-R22) show a significantly different ‘stiffening’ spring 
behavior, wherein the unfolding forces have a 3 to 5-fold increase for the 10th unfolding 
event compared to the 1st. The full length Utrophin variants (two halves combined 
together to form Utr FL and Utr R1-R22) show a strongly stiffening spring behavior with 4 
to 6-fold increases for the 10th unfolding events compared to their 1st.  
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Figure 4.9: Comparison of peak unfolding force vs unfolding event count shows 
brittle vs stiffening behavior of utrophin constructs. Peak unfolding force expressed 
as a function of the number of domains unfolded (Rupture Count). Data is averaged over 
300-500 successful pulling experiments for each protein construct. Utr NT-R10 and R1-
10 show brittle behavior whereas Utr FL, Utr R1-22, Utr R11-CT, and Utr R1-22 all show 
stiffening spring behavior.  
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Figure 4.10: Box plots of contour lengths as a function of unfolding count. These 
figures show contour length increasing linearly with unfolding events, where unfolding 
events are represented as ‘Ni’, i = {1,2,3…} and ‘d’ denotes the number of pulling 
experiments that resulted in ‘Ni’ events. A nearly linear increase in the contour length is 
expected as the unfolding events occur. 
  116 
 
Chapter 5 
 
Conclusions and Discussion 
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Thesis Findings 
 In addressing the questions proposed at the beginning of my thesis, my major 
findings are as follows:  
         
How do deletions present in therapeutically relevant, internally truncated dystrophins 
affect in vitro protein stability? 
 Dystrophin stability is context-dependent: relatively unaffected by small deletions 
at natural exon boundaries but sensitive to larger and more complex rearrangements 
from deletions present in gene therapy constructs. 
 
How are missense dystrophin proteins regulated in murine models of DMD and BMD 
missense mutants?  
 Missense dystrophin protein abundance inversely correlates with disease severity 
and positively correlates with levels of an E3 ubiquitin ligase identified in an siRNA 
screen for dystrophin-specific ubiquitin-conjugating enzymes, supporting our hypothesis 
that missense mutants are targeted to the proteasome for degradation.  
 
What are the mechanical properties of full-length utrophin and functionally relevant 
utrophin fragments?  
 We demonstrated that there are dramatic differences in the mechanical properties 
of two structurally homologous utrophin constructs both dominated by repetitive spectrin-
like motifs and that full-length utrophin exhibits unfolding forces and stiffening behavior 
more similar to titin than to spectrin.  
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Analysis of Dystrophin Protein Stability In Vitro and In Vivo 
 Despite its large size, full-length dystrophin is a highly stable protein, 
demonstrating cooperative unfolding as measured by circular dichroism spectroscopy 
(Henderson et al., 2010). However, a meta-analysis of similar in vitro thermodynamic 
measurements of dystrophin spectrin-like repeats, functional domains, and exon-skipped 
fragments reveals substantial heterogeneity with a broad range of stabilities compared to 
full-length dystrophin (see Chapter 1, Figure 1.4) (Bhasin et al., 2005; Legardinier et al., 
2008, 2009; Ruszczak et al., 2009; Krieger et al., 2010; Mirza et al., 2010; Henderson et 
al., 2011; Sahni et al., 2012). We have shown here that internally deleted dystrophins 
representing therapeutic micro-dystrophins also display variability in in vitro stability 
while exon-skipped dystrophins exhibit stability profiles congruent with the full-length 
protein (Chapter 2, McCourt et al. 2015).  
 The variability we see in thermodynamic stability of AAV gene therapy micro-
dystrophins appears to be dependent on the nature of the non-native junction created by 
the internal deletion. In comparing our data to studies on the same micro-dystrophins in 
mdx mice and the GRMD dog model, it is surprising that proteins displaying significant 
instability in vitro demonstrate significant efficacy in rescuing the dystrophic phenotype in 
mouse and dog models, even for the µH2 and ∆H2-R15∆CT constructs exhibiting the 
greatest instability (Wang et al., 2007; Lai et al., 2009; Banks et al., 2010; Wang et al., 
2012; Lai et al., 2013; Shin et al., 2013). The levels of micro-dystrophins expressed in 
animal models, however, were substantially higher than native dystrophin in wild-type 
mice, raising the possibility that putatively misfolded micro-dystrophins are evading the 
protein quality control pathways in vivo. The stability profile for the ∆3990 construct was 
most similar to full-length dystrophin and that showed similar efficacy in mdx mice was 
used in a clinical trial that reported minimal recombinant dystrophin expression 
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associated with a strong immune response to dystrophin. Clinical trials of optimized 
micro-dystrophins are expected in the near future. It is evident from our work together 
with pre-clinical animal studies and a single clinical trial that it is difficult to predict clinical 
efficacy from in vitro and in vivo murine models and requires additional understanding of 
how micro-dystrophins behave in the complex environment of a human muscle cell.  
 The exon-skipped dystrophins analyzed in our study represent the predicted 
protein products of anti-sense oligonucleotide (ASO) and morpholino drugs targeting 
out-of-frame deletions around exon 45 or 51 that could potentially treat 8% and 13% of 
DMD patients, respectively (Aartsma-Rus et al., 2009). Natural history studies on BMD 
patients with deletions mimicking those in DMD patients treated with exon-skipping 
drugs suggested that deletions spanning exon 45 were associated with lower levels of 
dystrophin and a more severe phenotype than those spanning exon 51 (Findlay et al., 
2015; Bello et al., 2016). Interestingly, both exon-45 and exon-51 skipped dystrophins in 
our study displayed in vitro stabilities consistent with full-length dystrophin suggesting 
that in vitro stability does not predict functionality in vivo. Additional clinical data for exon-
51 skipped dystrophins is now available following the recent approval of the morpholino 
drug, eteplirsen. The primary endpoint for the clinical trial was dystrophin restoration and 
western blot analysis of dystrophin levels in patients treated with the drug revealed 
increases in dystrophin protein from 0.28% to 0.93% (Aartsma-Rus and Krieg, 2017; 
Center for Drug Evaluation and Research, Application Number: 206488Orig1s000, 
2016). Additionally, initial analysis of functional improvement as measured by the 6-
minute walk test demonstrated a slower decrease in the distance walked for eteplirsen-
treated patients but the significance of this result is debated. Despite the lack of robust 
dystrophin restoration and clinical improvement, the small increase in dystrophin levels 
establishes that eteplirsen is producing its intended effect. There are several factors that 
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might be influencing eteplirsen’s efficiency including drug uptake, pharmacokinetics, 
targeting efficiency, as well as protein stability. Thus, continuing to determine how 
deletions resulting from exon-skipping affect protein stability in vivo is important for 
optimizing exon-skipping therapies.  
 To address the consequences of dystrophin instability in vivo, we have generated 
two novel transgenic mouse models expressing missense mutant dystrophins reported 
in human DMD (L54R) and BMD (L172H) patients (Chapter 3). The L54R and L172H 
missense mutants were previously evaluated in cultured myoblasts and shown to have 
missense-mutant dystrophin levels that were inversely proportional to in vitro stability 
and disease severity of the corresponding patients (Talsness et al., 2015). Analysis of 
the L54R and L172H mouse lines as well as a homozygous L172H mouse revealed that 
disease severity inversely correlates with expression levels of dystrophin protein.  
 Because missense dystrophin protein was increased in response to proteasome 
inhibition in the cell culture models, we hypothesized that the L54R and L172H proteins 
were also being targeted for degradation to the proteasome in the mouse lines. The 
ubiquitin-proteasome pathway is the major pathway for selective protein degradation as 
a means of quality control and protein homeostasis and is a highly specific and 
coordinated cascade of events involving ubiquitin-conjugating enzymes (Cohen-Kaplan 
et al., 2016). Ubiquitin-conjugating enzymes are categorized as ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2), or ubiquitin protein ligases (E3) and 
together, an E1, E2, and E3 ligase coordinate the transfer of a ubiquitin molecule to a 
specific target protein (Iconomou and Saunders, 2016). To determine the specific ligases 
involved in targeting missense dystrophins to the proteasome, we used an siRNA library 
of over 500 E1, E2, and E3 ligases in cultured myoblasts and identified five E3 ligases – 
Rnf182, VPS41, Zfand5, Amn1, and FBXO33. We detected Amn1 and FBXO33 proteins 
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in muscle tissues from our mouse lines and measured significant increases in both 
Amn1 and FBXO33 in the missense mouse lines compared to wild type and mdx mice. 
Amn1 protein levels also correlated with the amount of missense dystrophin present. 
Since treatment of mice with broad-spectrum proteasome inhibitors did not increase 
missense dystrophin levels in the mice, we plan to continue to investigate the role of the 
five putative dystrophin-specific E3 ligases in missense dystrophin biology in mouse 
models and in patients with the goal of establishing new therapeutic targets.   
 In future studies, we aim to determine whether knocking out or knocking down any 
of the E3 ligases causes an increase in dystrophin levels in mice. Of the five E3 ligases 
we identified, there is currently only a knockout mouse of Zfand5 available that would be 
used for generating a knockout model on the transgenic missense dystrophin 
background (Hishiya et al., 2006). We will utilize siRNAs in complex with atelocollagen 
for cell delivery to target Rnf182, VPS41, Amn1, and FBXO33 for knockdown in muscle 
(Kawakami et al., 2013) and analyze for E3 ligase levels, dystrophin protein levels, 
dystrophin ubiquitination, and improvement in dystrophic phenotype. A recent study on 
miRNA regulation of dystrophin identified dystrophin-targeting miRNAs that inversely 
correlated with dystrophin protein levels in mdx mice treated with exon skipping 
morpholinos, the GRMD canine model, and patient biopsies (Fiorillo et al., 2015). 
Therefore, we will measure dystrophin-targeting miRNAs in muscle tissues from L54R, 
L172H, and homozygous L172H mice.  To apply our studies to human patients, we will 
evaluate dystrophin-specific E3 ligase expression in BMD patient samples that have 
reduced dystrophin expression.  
 The overall aim of our proposed studies is identification of a therapeutic target for 
missense dystrophins but any findings would have implications for other mutation types 
and other therapeutic strategies. Protein instability caused by in-frame deletions found in 
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BMD patients can manifest as decreased dystrophin expression and thus inhibiting the 
degradation of dystrophin by the proteasome would be clinically beneficial (Anthony et 
al., 2011). Furthermore, dystrophin-specific E3 ligase inhibition could be used as an 
adjuvant treatment to exon-skipping drugs or gene therapies to optimize dystrophin 
restoration.  
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Mechanical Properties of Muscle Proteins 
 In contrast to dystrophin, utrophin displays uniform thermal stability upon internal 
deletion or terminal truncation (Henderson et al., 2011). However, in the first ever 
mechanical characterization of utrophin presented in Chapter 4, we measured 
remarkably different mechanical stabilities for terminal halves of utrophin by atomic force 
microscopy (AFM). The N-terminal half that binds actin filaments displayed uniform 
unfolding forces upon extension, demonstrating a “brittle” behavior. The C-terminal half 
and full-length utrophin showed increasing unfolding forces with extension that is 
characteristic of stiffening spring behavior. We determined that the observed mechanical 
differences are not influenced by the unique amino- and carboxy-terminal domains but 
rather are likely influenced by sequence differences in the spectrin-like repeats 
themselves, a phenomenon that has not been previously reported for other spectrin 
repeats. Indeed, the spectrin-like repeats of dystrophin and utrophin have much weaker 
conservation between repeat units compared to repeats within the spectrins (Winder et 
al., 1995). 
 Another surprising finding from our study was that unfolding forces measured for 
utrophin are much higher than those measured for spectrin and fragments of the 
dystrophin central rod domain (>100 pN compared to ~25 pN) (Rief et al., 1999; Bhasin 
et al., 2005; Krieger et al., 2010). The high unfolding forces of utrophin are not consistent 
with forces measured for plasma membrane adhesion complexes such as integrins and 
cadherins where forces do not exceed 25 pN, likely ruling out a spring-like mechanical 
role for utrophin at the membrane. The mechanical properties of utrophin are more 
consistent with the mechanically stiff muscle protein, titin that has unfolding forces in the 
range of 100-300 pN (Rief et al., 1997; Kellermayer et al., 2003; Zhu et al., 2009). In 
adult skeletal muscle, utrophin is localized to the myotendinous junction (MTJ) where 
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titin functions as a restorative elastic element (Ohlendieck et al., 1991; Charvet et al., 
2012). 
 Titin is a giant muscle protein that spans the distance from the Z-disk to the M-line 
of a sarcomere with functions including regulation of assembly and length of the thick 
filament, signaling, and development of passive force (reviewed in Granzier and Labeit 
2007).  The elasticity of titin can be attributed to structures in the I-band composed of 
repeated immunoglobulin (Ig) domains made of β-sandwich folds and a PEVK (rich in 
proline, glutamate, valine, arginine) domain containing coiled structures (Linke et al., 
1998; Linke and Grutzner, 2008). Experiments on stretch-induced translational 
movement using antibodies against the I-band components demonstrated that the Ig-
domains and PEVK domains contribute differently to the elasticity of titin (Linke et al., 
1996). At short sarcomere lengths and low passive force, the Ig domains are lengthened 
whereas at moderate to long sarcomere lengths and high passive force, the PEVK 
domain lengthens while the remaining Ig domains resist force. By AFM, Ig domains 
display increasing unfolding forces upon extension (Kellermayer et al., 2003), 
characteristic of stiffening spring behavior and similar to what we observed for the C-
terminal half and full-length utrophin proteins. AFM measurements for the PEVK domain 
show unfolding forces that are uniform upon extension, a property that is comparable to 
what we observed the N-terminal actin-binding half of utrophin. Interestingly, the PEVK 
domain of titin also binds actin (Yamasaki et al., 2001; Kulke et al., 2001; Linke et al., 
2002; Nagy et al., 2004). Based on our initial observations on comparing mechanical 
properties and localization of utrophin and titin, we hypothesize that utrophin may be 
acting in series with titin at the myotendinous junction.  
 Here we report novel findings on the properties of structurally homologous 
spectrin-like repeats in utrophin and on the potential function of utrophin at the 
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myotendinous junction. In future studies, we aim to optimize our AFM protocols to more 
efficiently attach protein molecules to the cantilever tip. We will design protein constructs 
with N- and C-terminal sequence tags (SpyTag and yBBr)  that provide chemistries for 
covalent linkages to the cantilever tip and the substrate base (Yin et al., 2006; Li et al., 
2014), ensuring secure attachment at the termini for more efficient and complete 
extension. We will continue to design and evaluate utrophin spectrin-like repeat 
constructs to establish a mechanism of mechanical stability differences. Analysis of R6-
15, R4-13, R8-17, and R18-22 are some of the constructs we propose in order to 
determine the influence of N-terminal vs C-terminal repeats on mechanical properties. 
Much of the work in our lab has focused on the differences between dystrophin and 
utrophin thus we will extend our AFM studies on functionally- and therapeutically 
relevant dystrophins as well as full-length dystrophin. To address our hypothesis that 
utrophin is acting in series with titin, we aim to evaluate utrophin-deficient mice for 
myotendinous junction defects, particularly passive stiffness. A mouse line deficient for 
both utrophin and α7 integrin has already been investigated and shown to have 
myotendinous junction defects (Welser et al., 2009) but any conclusions about the 
unique role of utrophin are confounded by an α7 integrin phenotype. Our proposed 
future studies will provide critical assessment of the mechanical functions of utrophin 
and dystrophin.  
  126 
References 
Aartsma-Rus, A., I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G.-J. van 
Ommen, and J.T. den Dunnen. 2009. Theoretic applicability of antisense-mediated 
exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30:293–9. 
doi:10.1002/humu.20918. 
Aartsma-Rus, A., and A.M. Krieg. 2017. FDA Approves Eteplirsen for Duchenne 
Muscular Dystrophy: The Next Chapter in the  Eteplirsen Saga. Nucleic Acid Ther. 
27:1–3. doi:10.1089/nat.2016.0657. 
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen 
in US & Canadian Subjects. 
Albrecht, D.E., and S.C. Froehner. 2002. Syntrophins and dystrobrevins: defining the 
dystrophin scaffold at synapses. Neurosignals. 11:123–129. doi:65053. 
Alter, J., F. Lou, A. Rabinowitz, H. Yin, J. Rosenfeld, S.D. Wilton, T.A. Partridge, and 
Q.L. Lu. 2006. Systemic delivery of morpholino oligonucleotide restores dystrophin 
expression bodywide and improves dystrophic pathology. Nat. Med. 12:175–7. 
doi:10.1038/nm1345. 
Amann, K.J., B.A. Renley, and J.M. Ervasti. 1998. A cluster of basic repeats in the 
dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. 
Chem. 273:28419–23. 
Anthony, K., S. Cirak, S. Torelli, G. Tasca, L. Feng, V. Arechavala-Gomeza, A. Armaroli, 
M. Guglieri, C.S. Straathof, J.J. Verschuuren, A. Aartsma-Rus, P. Helderman-van 
den Enden, K. Bushby, V. Straub, C. Sewry, A. Ferlini, E. Ricci, J.E. Morgan, and F. 
Muntoni. 2011. Dystrophin quantification and clinical correlations in Becker 
muscular dystrophy: implications for clinical trials. Brain. 134:3547–59. 
doi:10.1093/brain/awr291. 
Ayalon, G., J.Q. Davis, P.B. Scotland, and V. Bennett. 2008. An ankyrin-based 
mechanism for functional organization of dystrophin and dystroglycan. Cell. 
135:1189–1200. doi:10.1016/j.cell.2008.10.018. 
Banks, G.B., L.M. Judge, J.M. Allen, and J.S. Chamberlain. 2010. The polyproline site in 
hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 
6:e1000958. doi:10.1371/journal.pgen.1000958. 
Belanto, J.J., T.L. Mader, M.D. Eckhoff, D.M. Strandjord, G.B. Banks, M.K. Gardner, 
D.A. Lowe, and J.M. Ervasti. 2014. Microtubule binding distinguishes dystrophin 
from utrophin. Proc. Natl. Acad. Sci. U. S. A. 111:5723–8. 
doi:10.1073/pnas.1323842111. 
Bello, L., P. Campadello, A. Barp, M. Fanin, C. Semplicini, G. Soraru, L. Caumo, C. 
Calore, C. Angelini, and E. Pegoraro. 2016. Functional changes in Becker muscular 
dystrophy: implications for clinical trials in dystrophinopathies. Sci. Rep. 6:32439. 
doi:10.1038/srep32439. 
Bengtsson, N.E., J.K. Hall, G.L. Odom, M.P. Phelps, C.R. Andrus, R.D. Hawkins, S.D. 
Hauschka, J.R. Chamberlain, and J.S. Chamberlain. 2017. Muscle-specific 
CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse 
model for Duchenne muscular dystrophy. Nat. Commun. 8:14454. 
doi:10.1038/ncomms14454. 
Bhasin, N., R. Law, G. Liao, D. Safer, J. Ellmer, B.M. Discher, H.L. Sweeney, and D.E. 
Discher. 2005a. Molecular extensibility of mini-dystrophins and a dystrophin rod 
construct. J. Mol. Biol. 352:795–806. doi:10.1016/j.jmb.2005.07.064. 
Bhasin, N., R. Law, G. Liao, D. Safer, J. Ellmer, B.M. Discher, H.L. Sweeney, and D.E. 
  127 
Discher. 2005b. Molecular extensibility of mini-dystrophins and a dystrophin rod 
construct. J. Mol. Biol. 352:795–806. doi:10.1016/j.jmb.2005.07.064. 
Bhosle, R.C., D.E. Michele, K.P. Campbell, Z. Li, and R.M. Robson. 2006. Interactions of 
intermediate filament protein synemin with dystrophin and utrophin. Biochem. 
Biophys. Res. Commun. 346:768–77. doi:10.1016/j.bbrc.2006.05.192. 
Binnig, Quate, and Gerber. 1986. Atomic force microscope. Phys. Rev. Lett. 56:930–
933. doi:10.1103/PhysRevLett.56.930. 
Bladen, C.L., D. Salgado, S. Monges, M.E. Foncuberta, K. Kekou, K. Kosma, H. 
Dawkins, L. Lamont, A.J. Roy, T. Chamova, V. Guergueltcheva, S. Chan, L. 
Korngut, C. Campbell, Y. Dai, J. Wang, N. Barisic, P. Brabec, J. Lahdetie, M.C. 
Walter, O. Schreiber-Katz, V. Karcagi, M. Garami, V. Viswanathan, F. Bayat, F. 
Buccella, E. Kimura, Z. Koeks, J.C. van den Bergen, M. Rodrigues, R. Roxburgh, A. 
Lusakowska, A. Kostera-Pruszczyk, J. Zimowski, R. Santos, E. Neagu, S. 
Artemieva, V.M. Rasic, D. Vojinovic, M. Posada, C. Bloetzer, P.-Y. Jeannet, F. 
Joncourt, J. Diaz-Manera, E. Gallardo, A.A. Karaduman, H. Topaloglu, R. El Sherif, 
A. Stringer, A. V Shatillo, A.S. Martin, H.L. Peay, M.I. Bellgard, J. Kirschner, K.M. 
Flanigan, V. Straub, K. Bushby, J. Verschuuren, A. Aartsma-Rus, C. Beroud, and 
H. Lochmuller. 2015. The TREAT-NMD DMD Global Database: analysis of more 
than 7,000 Duchenne muscular  dystrophy mutations. Hum. Mutat. 36:395–402. 
doi:10.1002/humu.22758. 
Blake, D.J., D.R. Love, J. Tinsley, G.E. Morris, H. Turley, K. Gatter, G. Dickson, Y.H. 
Edwards, and K.E. Davies. 1992. Characterization of a 4.8kb transcript from the 
Duchenne muscular dystrophy locus expressed in Schwannoma cells. Hum. Mol. 
Genet. 1:103–109. 
Bodanovsky, A., N. Guttman, H. Barzilai-Tutsch, O. Genin, O. Levy, M. Pines, and O. 
Halevy. 2014. Halofuginone improves muscle-cell survival in muscular dystrophies. 
Biochim. Biophys. Acta. 1843:1339–1347. doi:10.1016/j.bbamcr.2014.03.025. 
Bonuccelli, G., F. Sotgia, W. Schubert, D.S. Park, P.G. Frank, S.E. Woodman, L. 
Insabato, M. Cammer, C. Minetti, and M.P. Lisanti. 2003. Proteasome inhibitor 
(MG-132) treatment of mdx mice rescues the expression and membrane 
localization of dystrophin and dystrophin-associated proteins. Am. J. Pathol. 
163:1663–1675. doi:10.1016/S0002-9440(10)63523-7. 
Briguet, A., I. Courdier-Fruh, M. Foster, T. Meier, and J.P. Magyar. 2004. Histological 
parameters for the quantitative assessment of muscular dystrophy in the mdx-
mouse. Neuromuscul. Disord. 14:675–682. doi:10.1016/j.nmd.2004.06.008. 
Buckley, C.D., J. Tan, K.L. Anderson, D. Hanein, N. Volkmann, W.I. Weis, W.J. Nelson, 
and A.R. Dunn. 2014. Cell adhesion. The minimal cadherin-catenin complex binds 
to actin filaments under force. Science. 346:1254211. 
doi:10.1126/science.1254211. 
Bulfield, G., W.G. Siller, P.A. Wight, and K.J. Moore. 1984. X chromosome-linked 
muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U. S. A. 81:1189–
1192. 
Bushby, K., R. Finkel, B. Wong, R. Barohn, C. Campbell, G.P. Comi, A.M. Connolly, 
J.W. Day, K.M. Flanigan, N. Goemans, K.J. Jones, E. Mercuri, R. Quinlivan, J.B. 
Renfroe, B. Russman, M.M. Ryan, M. Tulinius, T. Voit, S.A. Moore, H. Lee 
Sweeney, R.T. Abresch, K.L. Coleman, M. Eagle, J. Florence, E. Gappmaier, A.M. 
Glanzman, E. Henricson, J. Barth, G.L. Elfring, A. Reha, R.J. Spiegel, M.W. 
O’donnell, S.W. Peltz, and C.M. Mcdonald. 2014. Ataluren treatment of patients 
with nonsense mutation dystrophinopathy. Muscle Nerve. 50:477–487. 
  128 
doi:10.1002/mus.24332. 
Call, J.A., J.M. Ervasti, and D.A. Lowe. 2011. TAT-μUtrophin mitigates the 
pathophysiology of dystrophin and utrophin double-knockout mice. J. Appl. Physiol. 
111:200–5. doi:10.1152/japplphysiol.00248.2011. 
Campbell, C., H.J. McMillan, J.K. Mah, M. Tarnopolsky, K. Selby, T. McClure, D.M. 
Wilson, M.L. Sherman, D. Escolar, and K.M. Attie. 2016. Myostatin inhibitor ACE-
031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a 
randomized, placebo-controlled clinical trial. Muscle Nerve. doi:10.1002/mus.25268. 
Carlson, C.G., and R. V Makiejus. 1990. A noninvasive procedure to detect muscle 
weakness in the mdx mouse. Muscle Nerve. 13:480–4. 
doi:10.1002/mus.880130603. 
Carrion-Vazquez, M., A.F. Oberhauser, S.B. Fowler, P.E. Marszalek, S.E. Broedel, J. 
Clarke, and J.M. Fernandez. 1999. Mechanical and chemical unfolding of a single 
protein: a comparison. Proc. Natl. Acad. Sci. U. S. A. 96:3694–3699. 
Center for Drug Evaluation and Research, Application Number: 206488Orig1s000. 2016. 
Chamberlain, J.S., and G.M. Benian. 2000. Muscular dystrophy: the worm turns to 
genetic disease. Curr. Biol. 10:R795-7. 
Chang, A.C., A.H. Mekhdjian, M. Morimatsu, A.K. Denisin, B.L. Pruitt, and A.R. Dunn. 
2016. Single Molecule Force Measurements in Living Cells Reveal a Minimally 
Tensioned Integrin State. ACS Nano. 10:10745–10752. 
doi:10.1021/acsnano.6b03314. 
Charvet, B., F. Ruggiero, and D. Le Guellec. 2012. The development of the 
myotendinous junction. A review. Muscles. Ligaments Tendons J. 2:53–63. 
Cohen-Kaplan, V., I. Livneh, N. Avni, C. Cohen-Rosenzweig, and A. Ciechanover. 2016. 
The ubiquitin-proteasome system and autophagy: Coordinated and independent 
activities. Int. J. Biochem. Cell Biol. 79:403–418. doi:10.1016/j.biocel.2016.07.019. 
Cohn, R.D., and K.P. Campbell. 2000. Molecular basis of muscular dystrophies. Muscle 
Nerve. 23:1456–71. 
Connolly, A.M., R.M. Keeling, S. Mehta, A. Pestronk, and J.R. Sanes. 2001. Three 
mouse models of muscular dystrophy: the natural history of strength and fatigue in 
dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul. 
Disord. 11:703–712. 
Consolino, C.M., and S. V Brooks. 2004. Susceptibility to sarcomere injury induced by 
single stretches of maximally activated muscles of mdx mice. J. Appl. Physiol. 
96:633–638. doi:10.1152/japplphysiol.00587.2003. 
Cooper, B.J., N.J. Winand, H. Stedman, B.A. Valentine, E.P. Hoffman, L.M. Kunkel, 
M.O. Scott, K.H. Fischbeck, J.N. Kornegay, and R.J. Avery. 1988. The homologue 
of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature. 
334:154–156. doi:10.1038/334154a0. 
Deconinck, A.E., J.A. Rafael, J.A. Skinner, S.C. Brown, A.C. Potter, L. Metzinger, D.J. 
Watt, J.G. Dickson, J.M. Tinsley, and K.E. Davies. 1997. Utrophin-dystrophin-
deficient mice as a model for Duchenne muscular dystrophy. Cell. 90:717–727. 
Dennett, X., L.K. Shield, L.J. Clingan, and D.A. Woolley. 1988. Becker and Duchenne 
muscular dystrophy: a comparative morphological study. Aust. Paediatr. J. 24 Suppl 
1:15–20. 
van Deutekom, J.C., A. a Janson, I.B. Ginjaar, W.S. Frankhuizen, A. Aartsma-Rus, M. 
Bremmer-Bout, J.T. den Dunnen, K. Koop, A.J. van der Kooi, N.M. Goemans, S.J. 
de Kimpe, P.F. Ekhart, E.H. Venneker, G.J. Platenburg, J.J. Verschuuren, and G.-
J.B. van Ommen. 2007. Local dystrophin restoration with antisense oligonucleotide 
  129 
PRO051. N. Engl. J. Med. 357:2677–86. doi:10.1056/NEJMoa073108. 
Dowling, P., K. Culligan, and K. Ohlendieck. 2002. Distal mdx muscle groups exhibiting 
up-regulation of utrophin and rescue of dystrophin-associated glycoproteins 
exemplify a protected phenotype in muscular dystrophy. Naturwissenschaften. 
89:75–78. 
Ervasti, J.M. 2003. Costameres: the Achilles’ heel of Herculean muscle. J. Biol. Chem. 
278:13591–4. doi:10.1074/jbc.R200021200. 
Ervasti, J.M. 2007. Dystrophin, its interactions with other proteins, and implications for 
muscular dystrophy. Biochim. Biophys. Acta. 1772:108–17. 
doi:10.1016/j.bbadis.2006.05.010. 
Ervasti, J.M., and K.P. Campbell. 1991. Membrane organization of the dystrophin-
glycoprotein complex. Cell. 66:1121–1131. 
Filareto, A., S. Parker, R. Darabi, L. Borges, M. Iacovino, T. Schaaf, T. Mayerhofer, J.S. 
Chamberlain, J.M. Ervasti, R.S. McIvor, M. Kyba, and R.C.R. Perlingeiro. 2013. An 
ex vivo gene therapy approach to treat muscular dystrophy using inducible 
pluripotent stem cells. Nat. Commun. 4:1549. doi:10.1038/ncomms2550. 
Findlay, A.R., N. Wein, Y. Kaminoh, L.E. Taylor, D.M. Dunn, J.R. Mendell, W.M. King, A. 
Pestronk, J.M. Florence, K.D. Mathews, R.S. Finkel, K.J. Swoboda, M.T. Howard, 
J.W. Day, C. McDonald, A. Nicolas, E. Le Rumeur, R.B. Weiss, and K.M. Flanigan. 
2015. Clinical phenotypes as predictors of the outcome of skipping around DMD 
exon 45. Ann. Neurol. 77:668–674. doi:10.1002/ana.24365. 
Fiorillo, A.A., C.R. Heier, J.S. Novak, C.B. Tully, K.J. Brown, K. Uaesoontrachoon, M.C. 
Vila, P.P. Ngheim, L. Bello, J.N. Kornegay, C. Angelini, T.A. Partridge, K. Nagaraju, 
and E.P. Hoffman. 2015. TNF-alpha-Induced microRNAs Control Dystrophin 
Expression in Becker Muscular Dystrophy. Cell Rep. 12:1678–1690. 
doi:10.1016/j.celrep.2015.07.066. 
Flanigan, K.M. 2014. Duchenne and Becker muscular dystrophies. Neurol. Clin. 32:671–
88, viii. doi:10.1016/j.ncl.2014.05.002. 
Flood, W.D., R.W. Moyer, A. Tsykin, G.R. Sutherland, and S.A. Koblar. 2004. Nxf and 
Fbxo33: novel seizure-responsive genes in mice. Eur. J. Neurosci. 20:1819–1826. 
doi:10.1111/j.1460-9568.2004.03646.x. 
Fukada, S., D. Morikawa, Y. Yamamoto, T. Yoshida, N. Sumie, M. Yamaguchi, T. Ito, Y. 
Miyagoe-Suzuki, S. Takeda, K. Tsujikawa, and H. Yamamoto. 2010. Genetic 
Background Affects Properties of Satellite Cells and mdx Phenotypes. Am. J. 
Pathol. 176:2414–2424. doi:10.2353/ajpath.2010.090887. 
Gazzerro, E., S. Assereto, A. Bonetto, F. Sotgia, S. Scarfì, A. Pistorio, G. Bonuccelli, M. 
Cilli, C. Bruno, F. Zara, M.P. Lisanti, and C. Minetti. 2010. Therapeutic potential of 
proteasome inhibition in Duchenne and Becker muscular dystrophies. Am. J. 
Pathol. 176:1863–77. doi:10.2353/ajpath.2010.090468. 
Geng, L.N., Z. Yao, L. Snider, A.P. Fong, J.N. Cech, J.M. Young, S.M. van der Maarel, 
W.L. Ruzzo, R.C. Gentleman, R. Tawil, and S.J. Tapscott. 2012. DUX4 activates 
germline genes, retroelements, and immune mediators: implications  for 
facioscapulohumeral dystrophy. Dev. Cell. 22:38–51. 
doi:10.1016/j.devcel.2011.11.013. 
Gowers, W. 1886. A manual of diseases of the nervous system. London: Churchill. 
Grady, R.M., H. Teng, M.C. Nichol, J.C. Cunningham, R.S. Wilkinson, and J.R. Sanes. 
1997. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a 
model  for Duchenne muscular dystrophy. Cell. 90:729–738. 
Granzier, H., and S. Labeit. 2007. Structure-function relations of the giant elastic protein 
  130 
titin in striated and smooth muscle cells. Muscle Nerve. 36:740–755. 
doi:10.1002/mus.20886. 
Guiraud, S., H. Chen, D.T. Burns, and K.E. Davies. 2015. Advances in genetic 
therapeutic strategies for Duchenne muscular dystrophy. Exp. Physiol. 100:1458–
1467. doi:10.1113/EP085308. 
Guo, W.X., M. Nichol, and J.P. Merlie. 1996. Cloning and expression of full length 
mouse utrophin: the differential association of utrophin and dystrophin with AChR 
clusters. FEBS Lett. 398:259–264. 
Hamed, S., A. Sutherland-Smith, J. Gorospe, J. Kendrick-Jones, and E. Hoffman. 2005. 
DNA sequence analysis for structure/function and mutation studies in Becker 
muscular dystrophy. Clin. Genet. 68:69–79. doi:10.1111/j.1399-0004.2005.00455.x. 
Harper, S.Q., M.A. Hauser, C. DelloRusso, D. Duan, R.W. Crawford, S.F. Phelps, H.A. 
Harper, A.S. Robinson, J.F. Engelhardt, S. V Brooks, and J.S. Chamberlain. 2002. 
Modular flexibility of dystrophin: implications for gene therapy of Duchenne 
muscular dystrophy. Nat. Med. 8:253–61. doi:10.1038/nm0302-253. 
Heier, C.R., J.M. Damsker, Q. Yu, B.C. Dillingham, T. Huynh, J.H. Van der Meulen, A. 
Sali, B.K. Miller, A. Phadke, L. Scheffer, J. Quinn, K. Tatem, S. Jordan, S. Dadgar, 
O.C. Rodriguez, C. Albanese, M. Calhoun, H. Gordish-Dressman, J.K. Jaiswal, 
E.M. Connor, J.M. McCall, E.P. Hoffman, E.K.M. Reeves, and K. Nagaraju. 2013. 
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular 
dystrophy without side effects. EMBO Mol. Med. 5:1569–1585. 
doi:10.1002/emmm.201302621. 
Heller, K.N., C.L. Montgomery, K.M. Shontz, K.R. Clark, J.R. Mendell, and L.R. Rodino-
Klapac. 2015. Human alpha7 Integrin Gene (ITGA7) Delivered by Adeno-
Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-
Deficient Mice. Hum. Gene Ther. 26:647–656. doi:10.1089/hum.2015.062. 
Henderson, D.M., J.J. Belanto, B. Li, H. Heun-Johnson, and J.M. Ervasti. 2011. Internal 
deletion compromises the stability of dystrophin. Hum. Mol. Genet. 20:2955–63. 
doi:10.1093/hmg/ddr199. 
Henderson, D.M., A. Lee, and J.M. Ervasti. 2010. Disease-causing missense mutations 
in actin binding domain 1 of dystrophin induce thermodynamic instability and protein 
aggregation. Proc. Natl. Acad. Sci. U. S. A. 107:9632–7. 
doi:10.1073/pnas.1001517107. 
Hijikata, T., T. Murakami, H. Ishikawa, and H. Yorifuji. 2003. Plectin tethers desmin 
intermediate filaments onto subsarcolemmal dense plaques containing dystrophin 
and vinculin. Histochem. Cell Biol. 119:109–123. doi:10.1007/s00418-003-0496-5. 
Hishiya, A., S. Iemura, T. Natsume, S. Takayama, K. Ikeda, and K. Watanabe. 2006. A 
novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. EMBO J. 
25:554–564. doi:10.1038/sj.emboj.7600945. 
Hoffman, E.P., R.H. Brown, and L.M. Kunkel. 1987. Dystrophin : The Protein Product of 
the Duchenne Muscular Dystrophy Locus. Cell. 51:919–928. 
Hollinger, K., C.X. Yang, R.E. Montz, D. Nonneman, J.W. Ross, and J.T. Selsby. 2014. 
Dystrophin insufficiency causes selective muscle histopathology and loss of 
dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J.  Off. 
Publ. Fed. Am. Soc.  Exp. Biol. 28:1600–1609. doi:10.1096/fj.13-241141. 
Hotta, A. 2015. Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. J. 
Neuromuscul. Dis. 2:343–355. doi:10.3233/JND-150116. 
Huang, J., L. Teng, L. Li, T. Liu, L. Li, D. Chen, L.-G. Xu, Z. Zhai, and H.-B. Shu. 2004. 
ZNF216 Is an A20-like and IkappaB kinase gamma-interacting inhibitor of 
  131 
NFkappaB  activation. J. Biol. Chem. 279:16847–16853. 
doi:10.1074/jbc.M309491200. 
Hurchla, M.A., A. Garcia-Gomez, M.C. Hornick, E.M. Ocio, A. Li, J.F. Blanco, L. Collins, 
C.J. Kirk, D. Piwnica-Worms, R. Vij, M.H. Tomasson, A. Pandiella, J.F. San Miguel, 
M. Garayoa, and K.N. Weilbaecher. 2013. The epoxyketone-based proteasome 
inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and 
bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 27:430–40. 
doi:10.1038/leu.2012.183. 
Iconomou, M., and D.N. Saunders. 2016. Systematic approaches to identify E3 ligase 
substrates. Biochem. J. 473:4083–4101. doi:10.1042/BCJ20160719. 
Ishikawa-Sakurai, M., M. Yoshida, M. Imamura, K.E. Davies, and E. Ozawa. 2004. ZZ 
domain is essentially required for the physiological binding of dystrophin and 
utrophin to beta-dystroglycan. Hum. Mol. Genet. 13:693–702. 
doi:10.1093/hmg/ddh087. 
Jung, D., B. Yang, J. Meyer, J.S. Chamberlain, and K.P. Campbell. 1995. Identification 
and Characterization of the Dystrophin Anchoring Site on Beta-Dystroglycan. J. 
Biol. Chem. 270:27305–27310. doi:10.1074/jbc.270.45.27305. 
Karijolich, J., and Y.-T. Yu. 2014. Therapeutic suppression of premature termination 
codons: mechanisms and clinical  considerations (review). Int. J. Mol. Med. 34:355–
362. doi:10.3892/ijmm.2014.1809. 
Kawakami, E., N. Kawai, N. Kinouchi, H. Mori, Y. Ohsawa, N. Ishimaru, Y. Sunada, S. 
Noji, and E. Tanaka. 2013. Local applications of myostatin-siRNA with 
atelocollagen increase skeletal muscle mass and recovery of muscle function. 
PLoS One. 8:e64719. doi:10.1371/journal.pone.0064719. 
Kellermayer, M.S.Z., C. Bustamante, and H.L. Granzier. 2003. Mechanics and structure 
of titin oligomers explored with atomic force microscopy. Biochim. Biophys. Acta. 
1604:105–114. 
Khurana, T.S., E.P. Hoffman, and L.M. Kunkel. 1990. Identification of a chromosome 6-
encoded dystrophin-related protein. J. Biol. Chem. 265:16717–16720. 
Kinali, M., V. Arechavala-Gomeza, L. Feng, S. Cirak, D. Hunt, C. Adkin, M. Guglieri, E. 
Ashton, S. Abbs, P. Nihoyannopoulos, M.E. Garralda, M. Rutherford, C. McCulley, 
L. Popplewell, I.R. Graham, G. Dickson, M.J.A. Wood, D.J. Wells, S.D. Wilton, R. 
Kole, V. Straub, K. Bushby, C. Sewry, J.E. Morgan, and F. Muntoni. 2009. Local 
restoration of dystrophin expression with the morpholino oligomer AVI-4658 in 
Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, 
proof-of-concept study. Lancet Neurol. 8:918–28. doi:10.1016/S1474-
4422(09)70211-X. 
Kleopa, K. a, A. Drousiotou, E. Mavrikiou, A. Ormiston, and T. Kyriakides. 2006. 
Naturally occurring utrophin correlates with disease severity in Duchenne muscular 
dystrophy. Hum. Mol. Genet. 15:1623–8. doi:10.1093/hmg/ddl083. 
Kobayashi, Y.M., E.P. Rader, R.W. Crawford, N.K. Iyengar, D.R. Thedens, J.A. 
Faulkner, S. V Parikh, R.M. Weiss, J.S. Chamberlain, S.A. Moore, and K.P. 
Campbell. 2008. Sarcolemma-localized nNOS is required to maintain activity after 
mild exercise. Nature. 456:511–515. doi:10.1038/nature07414. 
Koenig, M., A.H. Beggs, M. Moyer, S. Scherpf, K. Heindrich, T. Bettecken, G. Meng, 
C.R. Muller, M. Lindlof, and H. Kaariainen. 1989. The molecular basis for Duchenne 
versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. 
J. Hum. Genet. 45:498–506. 
Koenig, M., E.P. Hoffman, C.J. Bertelson, A.P. Monaco, C. Feener, and L.M. Kunkel. 
  132 
1987. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and 
preliminary genomic organization of the DMD gene in normal and affected 
individuals. Cell. 50:509–517. 
Koenig, M., and L.M. Kunkel. 1990. Detailed analysis of the repeat domain of dystrophin 
reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. 
265:4560–6. 
Koenig, M., A.P. Monaco, and L.M. Kunkel. 1988. The complete sequence of dystrophin 
predicts a rod-shaped cytoskeletal protein. Cell. 53:219–228. 
Kohler, M., C.F. Clarenbach, C. Bahler, T. Brack, E.W. Russi, and K.E. Bloch. 2009. 
Disability and survival in Duchenne muscular dystrophy. J. Neurol. Neurosurg. 
Psychiatry. 80:320–325. doi:10.1136/jnnp.2007.141721. 
Kornegay, J.N., J.R. Bogan, D.J. Bogan, M.K. Childers, J. Li, P. Nghiem, D.A. Detwiler, 
C.A. Larsen, R.W. Grange, R.K. Bhavaraju-Sanka, S. Tou, B.P. Keene, J.F.J. 
Howard, J. Wang, Z. Fan, S.J. Schatzberg, M.A. Styner, K.M. Flanigan, X. Xiao, 
and E.P. Hoffman. 2012. Canine models of Duchenne muscular dystrophy and their 
use in therapeutic strategies. Mamm. Genome. 23:85–108. doi:10.1007/s00335-
011-9382-y. 
Krieger, C.C., N. Bhasin, M. Tewari, A.E.X. Brown, D. Safer, H.L. Sweeney, and D.E. 
Discher. 2010a. Exon-skipped dystrophins for treatment of Duchenne muscular 
dystrophy: mass spectrometry mapping of most exons and cooperative domain 
designs based on single molecule mechanics. Cytoskelet. 67:796–807. 
doi:10.1002/cm.20489. 
Krieger, C.C., N. Bhasin, M. Tewari, A.E.X. Brown, D. Safer, H.L. Sweeney, and D.E. 
Discher. 2010b. Exon-skipped dystrophins for treatment of Duchenne muscular 
dystrophy: mass spectrometry mapping of most exons and cooperative domain 
designs based on single molecule mechanics. Cytoskeleton (Hoboken). 67:796–
807. doi:10.1002/cm.20489. 
Kulke, M., S. Fujita-Becker, E. Rostkova, C. Neagoe, D. Labeit, D.J. Manstein, M. 
Gautel, and W.A. Linke. 2001. Interaction between PEVK-titin and actin filaments: 
origin of a viscous force component in cardiac myofibrils. Circ. Res. 89:874–881. 
Kunkel, L.M., E. Bachrach, R.R. Bennett, J. Guyon, and L. Steffen. 2006. Diagnosis and 
cell-based therapy for Duchenne muscular dystrophy in humans, mice, and 
zebrafish. J. Hum. Genet. 51:397–406. doi:10.1007/s10038-006-0374-9. 
Lai, Y., G. Thomas, Y. Yue, and H. Yang. 2009. Dystrophins carrying spectrin-like 
repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise 
performance in a mouse model of muscular. J. Clin. Investig. 119. 
doi:10.1172/JCI36612.624. 
Lai, Y., J. Zhao, Y. Yue, and D. Duan. 2012. α2 and α3 helices of dystrophin R16 and 
R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS 
binding. Proc. Natl. Acad. Sci. U. S. A. 
Lai, Y., J. Zhao, Y. Yue, and D. Duan. 2013. alpha2 and alpha3 helices of dystrophin 
R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for 
neuronal NOS binding. Proc. Natl. Acad. Sci. U. S. A. 110:525–530. 
doi:10.1073/pnas.1211431109. 
Law, R., P. Carl, S. Harper, P. Dalhaimer, D.W. Speicher, and D.E. Discher. 2003a. 
Cooperativity in forced unfolding of tandem spectrin repeats. Biophys. J. 84:533–
544. doi:10.1016/S0006-3495(03)74872-3. 
Law, R., G. Liao, S. Harper, G. Yang, D.W. Speicher, and D.E. Discher. 2003b. Pathway 
shifts and thermal softening in temperature-coupled forced unfolding of spectrin 
  133 
domains. Biophys. J. 85:3286–3293. doi:10.1016/S0006-3495(03)74747-X. 
Legardinier, S., J.-F. Hubert, O. Le Bihan, C. Tascon, C. Rocher, C. Raguénès-Nicol, A. 
Bondon, S. Hardy, and E. Le Rumeur. 2008. Sub-domains of the dystrophin rod 
domain display contrasting lipid-binding and stability properties. Biochim. Biophys. 
Acta. 1784:672–82. doi:10.1016/j.bbapap.2007.12.014. 
Legardinier, S., B. Legrand, C. Raguénès-Nicol, A. Bondon, S. Hardy, C. Tascon, E. Le 
Rumeur, and J.-F. Hubert. 2009a. A Two-amino Acid Mutation Encountered in 
Duchenne Muscular Dystrophy Decreases Stability of the Rod Domain 23 (R23) 
Spectrin-like Repeat of Dystrophin. J. Biol. Chem. 284:8822–32. 
doi:10.1074/jbc.M805846200. 
Legardinier, S., C. Raguénès-Nicol, C. Tascon, C. Rocher, S. Hardy, J.-F. Hubert, and 
E. Le Rumeur. 2009b. Mapping of the lipid-binding and stability properties of the 
central rod domain of human dystrophin. J. Mol. Biol. 389:546–58. 
doi:10.1016/j.jmb.2009.04.025. 
Li, D., A. Bareja, L. Judge, Y. Yue, Y. Lai, R. Fairclough, K.E. Davies, J.S. Chamberlain, 
and D. Duan. 2010. Sarcolemmal nNOS anchoring reveals a qualitative difference 
between dystrophin and utrophin. J. Cell Sci. 123:2008–13. doi:10.1242/jcs.064808. 
Li, D., Y. Yue, and D. Duan. 2008. Preservation of muscle force in Mdx3cv mice 
correlates with low-level expression  of a near full-length dystrophin protein. Am. J. 
Pathol. 172:1332–1341. doi:10.2353/ajpath.2008.071042. 
Li, L., J.O. Fierer, T.A. Rapoport, and M. Howarth. 2014. Structural analysis and 
optimization of the covalent association between SpyCatcher and a peptide Tag. J. 
Mol. Biol. 426:309–317. doi:10.1016/j.jmb.2013.10.021. 
Linke, W.A., and A. Grutzner. 2008. Pulling single molecules of titin by AFM--recent 
advances and physiological implications. Pflugers Arch. 456:101–115. 
doi:10.1007/s00424-007-0389-x. 
Linke, W.A., M. Ivemeyer, P. Mundel, M.R. Stockmeier, and B. Kolmerer. 1998. Nature 
of PEVK-titin elasticity in skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 95:8052–
8057. 
Linke, W.A., M. Ivemeyer, N. Olivieri, B. Kolmerer, J.C. Ruegg, and S. Labeit. 1996. 
Towards a molecular understanding of the elasticity of titin. J. Mol. Biol. 261:62–71. 
Linke, W.A., M. Kulke, H. Li, S. Fujita-Becker, C. Neagoe, D.J. Manstein, M. Gautel, and 
J.M. Fernandez. 2002. PEVK domain of titin: an entropic spring with actin-binding 
properties. J. Struct. Biol. 137:194–205. doi:10.1006/jsbi.2002.4468. 
Liu, Q.Y., J.X. Lei, M. Sikorska, and R. Liu. 2008. A novel brain-enriched E3 ubiquitin 
ligase RNF182 is up regulated in the brains of Alzheimer’s patients and targets 
ATP6V0C for degradation. Mol. Neurodegener. 3:4. doi:10.1186/1750-1326-3-4. 
Lloyd, T.E., and J.P. Taylor. 2010. Flightless flies: Drosophila models of neuromuscular 
disease. Ann. N. Y. Acad. Sci. 1184:e1-20. 
Long, C., L. Amoasii, A.A. Mireault, J.R. McAnally, H. Li, E. Sanchez-Ortiz, S. 
Bhattacharyya, J.M. Shelton, R. Bassel-Duby, and E.N. Olson. 2016. Postnatal 
genome editing partially restores dystrophin expression in a mouse model of 
muscular dystrophy. Science (80-. ). 351:400–403. doi:10.1126/science.aad5725. 
Long, C., J.R. McAnally, J.M. Shelton, A.A. Mireault, R. Bassel-Duby, and E.N. Olson. 
2014. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing 
of germline DNA. Science. 345:1184–1188. doi:10.1126/science.1254445. 
Love, D.R., D.F. Hill, G. Dickson, N.K. Spurr, B.C. Byth, R.F. Marsden, F.S. Walsh, Y.H. 
Edwards, and K.E. Davies. 1989. An autosomal transcript in skeletal muscle with 
homology to dystrophin. Nature. 339:55–58. doi:10.1038/339055a0. 
  134 
Lu, Q.L., A. Rabinowitz, Y.C. Chen, T. Yokota, H. Yin, J. Alter, A. Jadoon, G. Bou-
Gharios, and T. Partridge. 2005. Systemic delivery of antisense oligoribonucleotide 
restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. 
Sci. U. S. A. 102:198–203. doi:10.1073/pnas.0406700102. 
Lutz, M., F. Wempe, I. Bahr, D. Zopf, and H. von Melchner. 2006. Proteasomal 
degradation of the multifunctional regulator YB-1 is mediated by an F-Box protein 
induced during programmed cell death. FEBS Lett. 580:3921–3930. 
doi:10.1016/j.febslet.2006.06.023. 
Matsumura, K., J.M. Ervasti, K. Ohlendieck, S.D. Kahl, and K.P. Campbell. 1992. 
Assocation of dystrophin-related protein with dystrophin-associated proteins in mdx 
mouse muscle. Nature. 360:588–91. 
McCourt, J.L., K.K. Rhett, M.A. Jaeger, J.J. Belanto, D.M. Talsness, and J.M. Ervasti. 
2015. In vitro stability of therapeutically relevant, internally truncated dystrophins. 
Skelet. Muscle. 5:13. doi:10.1186/s13395-015-0040-z. 
McGreevy, J.W., C.H. Hakim, M.A. McIntosh, and D. Duan. 2015. Animal models of 
Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. 
Model. Mech. 8:195–213. doi:10.1242/dmm.018424. 
McVey Ward, D., D. Radisky, M.A. Scullion, M.S. Tuttle, M. Vaughn, and J. Kaplan. 
2001. hVPS41 is expressed in multiple isoforms and can associate with vesicles 
through  a RING-H2 finger motif. Exp. Cell Res. 267:126–134. 
doi:10.1006/excr.2001.5244. 
Megeney, L.A., B. Kablar, K. Garrett, J.E. Anderson, and M.A. Rudnicki. 1996. MyoD is 
required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 
10:1173–1183. 
Mendell, J. 2010. Dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl. J. 
Med. 1429–1437. 
Mendell, J.R., C. Shilling, N.D. Leslie, K.M. Flanigan, R. al-Dahhak, J. Gastier-Foster, K. 
Kneile, D.M. Dunn, B. Duval, A. Aoyagi, C. Hamil, M. Mahmoud, K. Roush, L. Bird, 
C. Rankin, H. Lilly, N. Street, R. Chandrasekar, and R.B. Weiss. 2012. Evidence-
based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 
71:304–13. doi:10.1002/ana.23528. 
Mirza, A., M. Sagathevan, N. Sahni, L. Choi, and N. Menhart. 2010. A biophysical map 
of the dystrophin rod. Biochim. Biophys. Acta. 1804:1796–809. 
doi:10.1016/j.bbapap.2010.03.009. 
Moens, P., P.H. Baatsen, and G. Marechal. 1993. Increased susceptibility of EDL 
muscles from mdx mice to damage induced by contractions with stretch. J. Muscle 
Res. Cell Motil. 14:446–451. 
Monaco, A.P., C.J. Bertelson, S. Liechti-Gallati, H. Moser, and L.M. Kunkel. 1988. An 
explanation for the phenotypic differences between patients bearing partial 
deletions of the DMD locus. Genomics. 2:90–95. 
Muntoni, F., S. Torelli, and A. Ferlini. 2003. Review Dystrophin and mutations : one gene 
, several proteins , multiple phenotypes. 44:731–740. 
Muthu, M., K. a. Richardson, and A.J. Sutherland-Smith. 2012. The Crystal Structures of 
Dystrophin and Utrophin Spectrin Repeats: Implications for Domain Boundaries. 
PLoS One. 7:e40066. doi:10.1371/journal.pone.0040066. 
Nagy, A., P. Cacciafesta, L. Grama, A. Kengyel, A. Malnasi-Csizmadia, and M.S.Z. 
Kellermayer. 2004. Differential actin binding along the PEVK domain of skeletal 
muscle titin. J. Cell Sci. 117:5781–5789. doi:10.1242/jcs.01501. 
Nelson, C.E., C.H. Hakim, D.G. Ousterout, P.I. Thakore, E.A. Moreb, R.M.C. Rivera, S. 
  135 
Madhavan, X. Pan, F.A. Ran, W.X. Yan, A. Asokan, F. Zhang, D. Duan, and C.A. 
Gersbach. 2016. In vivo genome editing improves muscle function in a mouse 
model of Duchenne muscular dystrophy. Science (80-. ). 351:403–407. 
doi:10.1126/science.aad5143. 
Nicolas, A., O. Delalande, J.-F. Hubert, and E. Le Rumeur. 2014a. The spectrin family of 
proteins: a unique coiled-coil fold for various molecular  surface properties. J. 
Struct. Biol. 186:392–401. doi:10.1016/j.jsb.2014.03.011. 
Nicolas, A., C. Lucchetti-Miganeh, R. Ben Yaou, J.-C. Kaplan, J. Chelly, F. Leturcq, F. 
Barloy-Hubler, and E. Le Rumeur. 2012. Assessment of the structural and 
functional impact of in-frame mutations of the DMD gene, using the tools included in 
the eDystrophin online database. Orphanet J. Rare Dis. 7:45. doi:10.1186/1750-
1172-7-45. 
Nicolas, A., C. Raguenes-Nicol, R. Ben Yaou, S. Ameziane-Le Hir, A. Cheron, V. Vie, M. 
Claustres, F. Leturcq, O. Delalande, J.-F. Hubert, S. Tuffery-Giraud, E. Giudice, 
and E. Le Rumeur. 2014b. Becker muscular dystrophy severity is linked to the 
structure of dystrophin. Hum. Mol. Genet. 
Niesen, F.H., H. Berglund, and M. Vedadi. 2007. The use of differential scanning 
fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 
2:2212–21. doi:10.1038/nprot.2007.321. 
Nonneman, D.J., T. Brown-Brandl, S.A. Jones, R.T. Wiedmann, and G.A. Rohrer. 2012. 
A defect in dystrophin causes a novel porcine stress syndrome. BMC Genomics. 
13:233. doi:10.1186/1471-2164-13-233. 
Norwood, F.L.,  a J. Sutherland-Smith, N.H. Keep, and J. Kendrick-Jones. 2000. The 
structure of the N-terminal actin-binding domain of human dystrophin and how 
mutations in this domain may cause Duchenne or Becker muscular dystrophy. 
Structure. 8:481–91. 
Odom, G.L., P. Gregorevic, J.M. Allen, E. Finn, and J.S. Chamberlain. 2008. 
Microutrophin delivery through rAAV6 increases lifespan and improves muscle 
function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16:1539–45. 
doi:10.1038/mt.2008.149. 
Ohlendieck, K., and K.P. Campbell. 1991. Dystrophin-associated proteins are greatly 
reduced in skeletal muscle from mdx mice. J. Cell Biol. 115:1685–1694. 
Ohlendieck, K., J.M. Ervasti, K. Matsumura, S.D. Kahl, C.J. Leveille, and K.P. Campbell. 
1991. Dystrophin-related protein is localized to neuromuscular junctions of adult 
skeletal muscle. Neuron. 7:499–508. 
Oudet, C., A. Hanauer, P. Clemens, T. Caskey, and J.L. Mandel. 1992. Two hot spots of 
recombination in the DMD gene correlate with the deletion prone  regions. Hum. 
Mol. Genet. 1:599–603. 
Ousterout, D.G., A.M. Kabadi, P.I. Thakore, W.H. Majoros, T.E. Reddy, and C.A. 
Gersbach. 2015. Multiplex CRISPR/Cas9-based genome editing for correction of 
dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 
6:6244. doi:10.1038/ncomms7244. 
Pascual, J., M. Pfuhl, D. Walther, M. Saraste, and M. Nilges. 1997. Solution structure of 
the spectrin repeat: a left-handed antiparallel triple-helical coiled-coil. J. Mol. Biol. 
273:740–51. doi:10.1006/jmbi.1997.1344. 
Petrof, B.J., J.B. Shrager, H.H. Stedman, A.M. Kelly, and H.L. Sweeney. 1993. 
Dystrophin protects the sarcolemma from stresses developed during muscle 
contraction. Proc. Natl. Acad. Sci. U. S. A. 90:3710–3714. 
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy. 
  136 
Phelps, S.F., M.A. Hauser, N.M. Cole, J.A. Rafael, R.T. Hinkle, J.A. Faulkner, and J.S. 
Chamberlain. 1995. Expression of full-length and truncated dystrophin mini-genes 
in transgenic mdx mice. Hum. Mol. Genet. 4:1251–1258. 
Prins, K.W., J.L. Humston, A. Mehta, V. Tate, E. Ralston, and J.M. Ervasti. 2009. 
Dystrophin is a microtubule-associated protein. J. Cell Biol. 186:363–9. 
doi:10.1083/jcb.200905048. 
Prior, T.W., A.C. Papp, P.J. Snyder, A.H. Burghes, C. Bartolo, M.S. Sedra, L.M. 
Western, and J.R. Mendell. 1993. A missense mutation in the dystrophin gene in a 
Duchenne muscular dystrophy patient. Nat. Genet. 4:357–360. 
doi:10.1038/ng0893-357. 
van Putten, M., M. Hulsker, V.D. Nadarajah, S.H. van Heiningen, E. van Huizen, M. van 
Iterson, P. Admiraal, T. Messemaker, J.T. den Dunnen, P.A.C. ’t Hoen, and A. 
Aartsma-Rus. 2012. The effects of low levels of dystrophin on mouse muscle 
function and pathology. PLoS One. 7:e31937. doi:10.1371/journal.pone.0031937. 
Rahimov, F., and L.M. Kunkel. 2013. The cell biology of disease: cellular and molecular 
mechanisms underlying muscular dystrophy. J. Cell Biol. 201:499–510. 
doi:10.1083/jcb.201212142. 
Rezniczek, G. a, P. Konieczny, B. Nikolic, S. Reipert, D. Schneller, C. Abrahamsberg, 
K.E. Davies, S.J. Winder, and G. Wiche. 2007. Plectin 1f scaffolding at the 
sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with 
beta-dystroglycan. J. Cell Biol. 176:965–77. doi:10.1083/jcb.200604179. 
Ricotti, V., S. Spinty, H. Roper, I. Hughes, B. Tejura, N. Robinson, G. Layton, K. Davies, 
F. Muntoni, and J. Tinsley. 2016. Safety, Tolerability, and Pharmacokinetics of SMT 
C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-
Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy. 
PLoS One. 11:e0152840. doi:10.1371/journal.pone.0152840. 
Rief, M., M. Gautel, F. Oesterhelt, J.M. Fernandez, and H.E. Gaub. 1997. Reversible 
unfolding of individual titin immunoglobulin domains by AFM. Science. 276:1109–
1112. 
Rief, M., J. Pascual, M. Saraste, and H.E. Gaub. 1999. Single molecule force 
spectroscopy of spectrin repeats: low unfolding forces in helix bundles. J. Mol. Biol. 
286:553–561. doi:10.1006/jmbi.1998.2466. 
Rigoletto, C., A. Prelle, P. Ciscato, M. Moggio, G. Comi, F. Fortunato, and G. Scarlato. 
1995. Utrophin expression during human fetal development. Int. J. Dev. Neurosci. 
13:585–593. 
Rodrigues, M., Y. Echigoya, R. Maruyama, K.R.Q. Lim, S. Fukada, and T. Yokota. 2016. 
Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-
deficient mdx muscles on DBA/2 background. Sci. Rep. 6:38371. 
doi:10.1038/srep38371. 
Ruszczak, C., A. Mirza, and N. Menhart. 2009. Differential stabilities of alternative exon-
skipped rod motifs of dystrophin. Biochim. Biophys. Acta. 1794:921–8. 
doi:10.1016/j.bbapap.2009.02.016. 
Rybakova, I.N., K.J. Amann, and J.M. Ervasti. 1996. A new model for the interaction of 
dystrophin with F-actin. J. Cell Biol. 135:661–72. 
Rybakova, I.N., and J.M. Ervasti. 1997. Dystrophin-glycoprotein complex is monomeric 
and stabilizes actin filaments in vitro through a lateral association. J. Biol. Chem. 
272:28771–8. 
Rybakova, I.N., J.L. Humston, K.J. Sonnemann, and J.M. Ervasti. 2006. Dystrophin and 
utrophin bind actin through distinct modes of contact. J. Biol. Chem. 281:9996–
  137 
10001. doi:10.1074/jbc.M513121200. 
Rybakova, I.N., J.R. Patel, K.E. Davies, P.D. Yurchenco, and J.M. Ervasti. 2002a. 
Utrophin Binds Laterally along Actin Filaments and Can Couple Costameric Actin 
with Sarcolemma When Overexpressed in Dystrophin-deficient Muscle. 13:1512–
1521. doi:10.1091/mbc.01. 
Rybakova, I.N., J.R. Patel, K.E. Davies, P.D. Yurchenco, and J.M. Ervasti. 2002b. 
Utrophin binds laterally along actin filaments and can couple costameric actin with 
sarcolemma when overexpressed in dystrophin-deficient muscle. Mol. Biol. Cell. 
13:1512–1521. doi:10.1091/mbc.01-09-0446. 
Rybakova, I.N., J.R. Patel, and J.M. Ervasti. 2000. The Dystrophin Complex Forms a 
Mechanically Strong Link between the Sarcolemma and Costameric Actin. J. Cell 
Biol. 150:1209–1214. doi:10.1083/jcb.150.5.1209. 
Saadat, L., L. Pittman, and N. Menhart. 2006. Structural cooperativity in spectrin type 
repeats motifs of dystrophin. Biochim. Biophys. Acta. 1764:943–54. 
doi:10.1016/j.bbapap.2006.02.012. 
Sahni, N., K. Mangat, E. Le Rumeur, and N. Menhart. 2012. Exon edited dystrophin rods 
in the hinge 3 region. Biochim. Biophys. Acta. 1824:1080–1089. 
doi:10.1016/j.bbapap.2012.06.011. 
Sakamoto, M., K. Yuasa, M. Yoshimura, T. Yokota, T. Ikemoto, M. Suzuki, G. Dickson, 
Y. Miyagoe-Suzuki, and S. Takeda. 2002. Micro-dystrophin cDNA ameliorates 
dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. 
Biophys. Res. Commun. 293:1265–72. doi:10.1016/S0006-291X(02)00362-5. 
Shin, J.-H., X. Pan, C.H. Hakim, H.T. Yang, Y. Yue, K. Zhang, R.L. Terjung, and D. 
Duan. 2013. Microdystrophin ameliorates muscular dystrophy in the canine model 
of duchenne muscular dystrophy. Mol. Ther. 21:750–757. doi:10.1038/mt.2012.283. 
Sicinski, P., Y. Geng, A.S. Ryder-Cook, E.A. Barnard, M.G. Darlison, and P.J. Barnard. 
1989. The molecular basis of muscular dystrophy in the mdx mouse: a point 
mutation. Science. 244:1578–1580. 
Singh, S.M., N. Kongari, J. Cabello-Villegas, and K.M.G. Mallela. 2010. Missense 
mutations in dystrophin that trigger muscular dystrophy decrease protein stability 
and lead to cross-beta aggregates. Proc. Natl. Acad. Sci. U. S. A. 107:15069–74. 
doi:10.1073/pnas.1008818107. 
Sonnemann, K.J., H. Heun-Johnson, A.J. Turner, K.A. Baltgalvis, D.A. Lowe, and J.M. 
Ervasti. 2009. Functional substitution by TAT-utrophin in dystrophin-deficient mice. 
PLoS Med. 6:e1000083. doi:10.1371/journal.pmed.1000083. 
Stessman, H.A.F., L.B. Baughn, A. Sarver, T. Xia, R. Deshpande, A. Mansoor, S.A. 
Walsh, J.J. Sunderland, N.G. Dolloff, M.A. Linden, F. Zhan, S. Janz, C.L. Myers, 
and B.G. Van Ness. 2013. Profiling Bortezomib Resistance Identifies Secondary 
Therapies in a Mouse Myeloma Model. Mol. Cancer Ther. 12:1140–1150. 
doi:10.1158/1535-7163.MCT-12-1151. 
Stone, M.R., A.O. Neill, D. Catino, and R.J. Bloch. 2005. Specific Interaction of the Actin-
binding Domain of Dystrophin with Intermediate Filaments Containing Keratin 19. 
Mol. Biol. Cell. 16:4280–4293. doi:10.1091/mbc.E05. 
Suzuki, A., M. Yoshida, H. Yamamoto, and E. Ozawa. 1992. Glycoprotein-binding site of 
dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-
terminal domain. FEBS Lett. 308:154–160. 
Tabebordbar, M., K. Zhu, J.K.W. Cheng, W.L. Chew, J.J. Widrick, W.X. Yan, C. 
Maesner, E.Y. Wu, R. Xiao, F.A. Ran, L. Cong, F. Zhang, L.H. Vandenberghe, G.M. 
Church, and A.J. Wagers. 2016. In vivo gene editing in dystrophic mouse muscle 
  138 
and muscle stem cells. Science (80-. ). 351:407–411. 
doi:10.1126/science.aad5177. 
Talsness, D.M., J.J. Belanto, and J.M. Ervasti. 2015. Disease-proportional proteasomal 
degradation of missense dystrophins. Proc. Natl. Acad. Sci. U. S. A. 112:12414–9. 
doi:10.1073/pnas.1508755112. 
Tanabe, Y., K. Esaki, and T. Nomura. 1986. Skeletal muscle pathology in X 
chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol. 69:91–95. 
Tinsley, J., N. Deconinck, R. Fisher, D. Kahn, S. Phelps, J.M. Gillis, and K. Davies. 
1998. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. 
Nat. Med. 4:1441–4. doi:10.1038/4033. 
Tinsley, J.M., R.J. Fairclough, R. Storer, F.J. Wilkes, A.C. Potter, S.E. Squire, D.S. 
Powell, A. Cozzoli, R.F. Capogrosso, A. Lambert, F.X. Wilson, S.P. Wren, A. De 
Luca, and K.E. Davies. 2011. Daily Treatment with SMTC1100, a Novel Small 
Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in 
the mdx Mouse. PLoS One. 6:e19189. doi:10.1371/journal.pone.0019189. 
Valentine, B.A., B.J. Cooper, J.F. Cummings, and A. deLahunta. 1986. Progressive 
muscular dystrophy in a golden retriever dog: light microscope and ultrastructural 
features at 4 and 8 months. Acta Neuropathol. 71:301–310. 
Wada, Y. 2013. Vacuoles in mammals: a subcellular structure indispensable for early 
embryogenesis. Bioarchitecture. 3:13–19. doi:10.4161/bioa.24126. 
Wang, B., J. Li, and X. Xiao. 2000. Adeno-associated virus vector carrying human 
minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse 
model. Proc. Natl. Acad. Sci. U. S. A. 97:13714–9. doi:10.1073/pnas.240335297. 
Wang, Y., T. Shirogane, D. Liu, J.W. Harper, and S.J. Elledge. 2003. Exit from exit: 
resetting the cell cycle through Amn1 inhibition of G protein signaling. Cell. 
112:697–709. 
Wang, Z., C.S. Kuhr, J.M. Allen, M. Blankinship, P. Gregorevic, J.S. Chamberlain, S.J. 
Tapscott, and R. Storb. 2007. Sustained AAV-mediated dystrophin expression in a 
canine model of Duchenne muscular dystrophy with a brief course of 
immunosuppression. Mol. Ther. 15:1160–6. doi:10.1038/sj.mt.6300161. 
Wang, Z., R. Storb, C.L. Halbert, G.B. Banks, T.M. Butts, E.E. Finn, J.M. Allen, A.D. 
Miller, J.S. Chamberlain, and S.J. Tapscott. 2012. Successful regional delivery and 
long-term expression of a dystrophin gene in canine muscular dystrophy: a 
preclinical model for human therapies. Mol. Ther. 20:1501–7. 
doi:10.1038/mt.2012.111. 
Warner, L.E., C. DelloRusso, R.W. Crawford, I.N. Rybakova, J.R. Patel, J.M. Ervasti, 
and J.S. Chamberlain. 2002. Expression of Dp260 in muscle tethers the actin 
cytoskeleton to the dystrophin-glycoprotein complex and partially prevents 
dystrophy. Hum. Mol. Genet. 11:1095–105. 
Way, M., B. Pope, R.A. Cross, J. Kendrick-Jones, and A.G. Weeds. 1992. Expression of 
the N-terminal domain of dystrophin in E. coli and demonstration of binding to F-
actin. FEBS Lett. 301:243–5. 
Weathington, N.M., and R.K. Mallampalli. 2014. Emerging therapies targeting the 
ubiquitin proteasome system in cancer. J. Clin. Invest. 124:6–12. 
doi:10.1172/JCI71602. 
Wells, D.J., K.E. Wells, E.A. Asante, G. Turner, Y. Sunada, K.P. Campbell, F.S. Walsh, 
and G. Dickson. 1995. Expression of human full-length and minidystrophin in 
transgenic mdx mice: implications for gene therapy of Duchenne muscular 
dystrophy. Hum. Mol. Genet. 4:1245–1250. 
  139 
Welser, J. V, J.E. Rooney, N.C. Cohen, P.B. Gurpur, C.A. Singer, R.A. Evans, B.A. 
Haines, and D.J. Burkin. 2009. Myotendinous junction defects and reduced force 
transmission in mice that lack alpha7 integrin and utrophin. Am. J. Pathol. 
175:1545–1554. doi:10.2353/ajpath.2009.090052. 
Winder, S.J., T.J. Gibson, and J. Kendrick-Jones. 1995. Dystrophin and utrophin: the 
missing links! FEBS Lett. 369:27–33. 
Xu, L., K.H. Park, L. Zhao, J. Xu, M. El Refaey, Y. Gao, H. Zhu, J. Ma, and R. Han. 
2016. CRISPR-mediated Genome Editing Restores Dystrophin Expression and 
Function in mdx Mice. Mol. Ther. 24:564–569. doi:10.1038/mt.2015.192. 
Yamasaki, R., M. Berri, Y. Wu, K. Trombitas, M. McNabb, M.S. Kellermayer, C. Witt, D. 
Labeit, S. Labeit, M. Greaser, and H. Granzier. 2001. Titin-actin interaction in 
mouse myocardium: passive tension modulation and its regulation by 
calcium/S100A1. Biophys. J. 81:2297–2313. doi:10.1016/S0006-3495(01)75876-6. 
Yamashita, K., A. Suzuki, Y. Satoh, M. Ide, Y. Amano, M. Masuda-Hirata, Y.K. Hayashi, 
K. Hamada, K. Ogata, and S. Ohno. 2010. The 8th and 9th tandem spectrin-like 
repeats of utrophin cooperatively form a functional unit to interact with polarity-
regulating kinase PAR-1b. Biochem. Biophys. Res. Commun. 391:812–817. 
doi:10.1016/j.bbrc.2009.11.144. 
Yang, J., Z. Wang, Y. Fang, J. Jiang, F. Zhao, H. Wong, M.K. Bennett, C.J. Molineaux, 
and C.J. Kirk. 2011. Pharmacokinetics, pharmacodynamics, metabolism, 
distribution, and excretion of carfilzomib in rats. Drug Metab. Dispos. 39:1873–82. 
doi:10.1124/dmd.111.039164. 
Yin, J., A.J. Lin, D.E. Golan, and C.T. Walsh. 2006. Site-specific protein labeling by Sfp 
phosphopantetheinyl transferase. Nat. Protoc. 1:280–285. 
doi:10.1038/nprot.2006.43. 
Young, C.S., M.R. Hicks, N.V. Ermolova, H. Nakano, M. Jan, S. Younesi, S. 
Karumbayaram, C. Kumagai-Cresse, D. Wang, J.A. Zack, D.B. Kohn, A. Nakano, 
S.F. Nelson, M.C. Miceli, M.J. Spencer, and A.D. Pyle. 2016. A Single CRISPR-
Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores 
Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell. 18:533–540. 
doi:10.1016/j.stem.2016.01.021. 
Zellweger, H., and A. Antonik. 1975. Newborn screening for Duchenne muscular 
dystrophy. Pediatrics. 55:30–34. 
Zhu, Y., J. Bogomolovas, S. Labeit, and H. Granzier. 2009. Single molecule force 
spectroscopy of the cardiac titin N2B element: effects of the molecular chaperone 
alphaB-crystallin with disease-causing mutations. J. Biol. Chem. 284:13914–13923. 
doi:10.1074/jbc.M809743200. 
 
 
 
 
 
 
 
 
 
 
 
 
